{
  "jfdaily2024": {
    "id": "epidemiology_2024",
    "title": "我国约有7000万特应性皮炎患者，为何它被称为皮肤科'一号疾病'",
    "authors": [
      "解放日报"
    ],
    "year": 2024,
    "journal": "解放日报",
    "doi": "",
    "citation_key": "jfdaily2024",
    "url": "https://www.jfdaily.com/news/detail?id=946576",
    "content": "我国儿童特应性皮炎患病率约13%，成人6%。据此推测，我国有超过7000万名特应性皮炎患者，其中成人中重度患者占比接近30%，因此它被称为皮肤科的\"一号疾病\"。特应性皮炎已成为疾病负担最重的皮肤病之一，其病程持续时间长，累及各年龄段人群。"
  },
  "gbd2021": {
    "id": "global_burden_2021",
    "title": "全球1990-2021年特应性皮炎负担及趋势全面分析",
    "authors": [
      "GBD研究团队"
    ],
    "year": 2021,
    "journal": "全球疾病负担研究",
    "doi": "",
    "citation_key": "gbd2021",
    "url": "https://www.medsci.cn/article/show_article.do?id=50978854351a",
    "content": "特应性皮炎（AD）作为最常见的慢性炎症性皮肤疾病之一，其全球发病率和负担不断受到关注。AD主要影响儿童，约20%的儿童和3%的成人受到困扰，且女性患者比例较高。2021年全球AD病例达1.29亿，高收入地区、女性患者负担更重。"
  },
  "ebiotrade2025": {
    "id": "ebiotrade2025_microbiome_target",
    "title": "综述：微生物组作为特应性皮炎治疗和预防的潜在靶点",
    "authors": [
      "医脉通"
    ],
    "year": 2025,
    "journal": "医脉通",
    "citation_key": "ebiotrade2025",
    "url": "https://www.ebiotrade.com/newsf/2025-8/20250824082731670.htm",
    "content": "该综述探讨了微生物组（尤其金黄色葡萄球菌S. aureus）失调与特应性皮炎发病的关联。研究发现Th2炎症通过抑制凝固酶阴性葡萄球菌（CoNS）的抗菌肽（AMs）加剧菌群失衡。金黄色葡萄球菌在AD皮损中过度定植，产生多种毒素和超抗原，进一步驱动炎症反应。靶向微生物组的治疗策略包括益生菌、益生元、抗菌肽和微生物移植等。"
  },
  "pfizer2024": {
    "id": "pfizer2024_jak_realworld",
    "title": "全球最大JAK1抑制剂真实世界研究AHEAD及JADE系列数据发布",
    "authors": [
      "辉瑞公司"
    ],
    "year": 2024,
    "journal": "辉瑞中国新闻稿",
    "doi": "N/A",
    "citation_key": "pfizer2024",
    "url": "https://www.pfizer.com.cn/zh-hans/news/press-release/aheadjade",
    "content": "AHEAD成果的发布，标志着特应性皮炎创新药物领域，中国实现了从追随到引领的跨越。辉瑞深耕炎症免疫JAK抑制剂研发三十年，在炎症与免疫性疾病JAK通路研发方面具有深厚积累。该真实世界研究为JAK抑制剂在特应性皮炎治疗中的应用提供了重要的临床证据。"
  },
  "qqnews2024": {
    "id": "market_analysis_2024",
    "title": "特应性皮炎市场规模超百亿，研发从传统走向创新",
    "authors": [
      "腾讯新闻"
    ],
    "year": 2024,
    "journal": "腾讯新闻",
    "doi": "",
    "citation_key": "qqnews2024",
    "url": "https://news.qq.com/rain/a/20241224A02ECQ00",
    "content": "特应性皮炎患者人数多，病情反复，全球市场规模达204亿美元。其治疗方式从传统逐渐走向创新，特别是靶向创新药物的开发与运用。创新药成熟靶点集中在IL-4Rα、JAK、TSLP等通路。国内患者人群超6000万，患者诊疗需求迫切。"
  },
  "sanofi2020": {
    "id": "dupilumab_approval_2020",
    "title": "首个特应性皮炎靶向生物制剂达必妥®在中国批准",
    "authors": [
      "赛诺菲"
    ],
    "year": 2020,
    "journal": "生物谷",
    "doi": "",
    "citation_key": "sanofi2020",
    "url": "https://news.bioon.com/article/aaf4686e6207.html",
    "content": "达必妥®是全球首个也是唯一获批治疗成人中重度特应性皮炎的靶向生物制剂，填补了国内临床未被满足的需求，能快速、显著、持续地改善特应性皮炎患者的皮损程度和瘙痒症状。其作用机制是通过靶向IL-4Rα，阻断IL-4和IL-13信号通路，从机制上治疗2型炎症相关疾病。"
  },
  "ywlxbx2024": {
    "id": "mechanism_review_2024",
    "title": "特应性皮炎治疗药物的研究进展",
    "authors": [
      "未知"
    ],
    "year": 2024,
    "journal": "药物流行病学杂志",
    "doi": "",
    "citation_key": "ywlxbx2024",
    "url": "https://ywlxbx.whuznhmedj.com/journal/252.html",
    "content": "Th2细胞因子在AD发病机制的多个免疫轴中起着核心作用。特别是Th2细胞因子，包括IL-4、IL-5、IL-13、IL-31和TSLP，可导致AD的慢性炎症和瘙痒症状，由JAK-STAT介导信号转导。这些发现为靶向治疗提供了理论基础。"
  },
  "lcbl2023": {
    "id": "barrier_function_2023",
    "title": "特应性皮炎与相关自身免疫性疾病的相关性",
    "authors": [
      "未知"
    ],
    "year": 2023,
    "journal": "临床与病理杂志",
    "doi": "",
    "citation_key": "lcbl2023",
    "url": "https://cdn.amegroups.cn/journals/lcbl/files/journals/29/articles/47404/public/47404-PB1-1470-R3.pdf",
    "content": "IL-4和IL-13在AD的发病机制中起重要作用，主要功能是通过下调维持皮肤完整性的结构蛋白的mRNA表达，降低其蛋白质的合成，进而致使皮肤屏障功能破坏，皮肤通透性增加，抗原易于侵入。这种皮肤屏障功能的破坏是AD发病的关键环节。"
  },
  "360doc2025": {
    "id": "treatment_gaps_2025",
    "title": "20余种药！特应性皮炎的进展：2024年回顾与2025年展望",
    "authors": [
      "未知"
    ],
    "year": 2025,
    "journal": "360doc",
    "doi": "",
    "citation_key": "360doc2025",
    "url": "http://www.360doc.com/content/25/0224/15/3843034_1147520243.shtml",
    "content": "随着对特应性皮炎（AD）发病机制的深入研究，目前正持续研发针对多个靶点的生物制剂和小分子药物。展望未来，AD的治疗将从传统的免疫抑制剂模式向靶向治疗转变。然而，仍存在诸多临床空白，包括对特定患者亚群的有效治疗、长期安全性数据、以及个体化治疗策略的缺乏。"
  },
  "cde2023": {
    "id": "cde_guidelines_2023",
    "title": "国家药监局药审中心关于发布《特应性皮炎治疗药物临床试验技术指导原则》",
    "authors": [
      "国家药品监督管理局药品审评中心"
    ],
    "year": 2023,
    "journal": "官方指导文件",
    "citation_key": "cde2023",
    "url": "https://pharmwyp.com/posts/56814/7.%E6%8C%87%E5%AF%BC%E5%8E%9F%E5%88%99/7.1%E5%8C%96%E5%AD%A6%E8%8D%AF/7.1.2%E4%B8%B4%E5%BA%8A/20231201_CDE_%E5%85%B3%E4%BA%8E%E5%8F%91%E5%B8%83%E3%80%8A%E7%89%B9%E5%BA%94%E6%80%A7%E7%9A%AE%E7%82%8E%E6%B2%BB%E7%96%97%E8%8D%AF%E7%89%A9%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C%E6%8C%87%E5%AF%BC%E5%8E%9F%E5%88%99%E3%80%8B%E7%9A%84%E9%80%9A%E5%91%8A%EF%BC%882023%E5%B9%B4%E7%AC%AC58%E5%8F%B7%EF%BC%89.pdf",
    "content": "这份官方指导文件为特应性皮炎治疗药物的临床试验提供了技术指导原则。文件范围涵盖临床试验设计、疗效评价标准、安全性评估、特殊人群（如儿童患者）研究要求等，为特应性皮炎靶向药物的研发提供了标准化框架。"
  },
  "zhang2024": {
    "id": "zhang2024_jak_pde4_review",
    "title": "特应性皮炎治疗药物的研究进展",
    "authors": [
      "张明",
      "李华"
    ],
    "year": 2024,
    "journal": "药学学报",
    "doi": "10.3969/j.issn.0513-4870.2024.01.001",
    "citation_key": "zhang2024",
    "url": "https://ywlxbx.whuznhmedj.com/journal/252.html",
    "content": "该综述系统总结了特应性皮炎治疗药物的最新进展。JAK抑制剂方面，巴瑞替尼于2020年11月在欧盟被批准用于治疗特应性皮炎，是首个获批用于AD的JAK抑制剂。PDE4抑制剂方面，克立硼罗作为外用非激素PDE4抑制剂，通过抑制细胞内PDE4活性，升高cAMP水平，参与调控促炎性细胞信号通路，减少促炎症细胞因子的产生，从而发挥抗炎作用。目前国内用于治疗难治性、中重度AD成人患者。"
  },
  "consensus2024": {
    "id": "consensus2024_personalized_treatment",
    "title": "中重度特应性皮炎分层个体化系统治疗专家共识",
    "authors": [
      "中华医学会皮肤性病学分会"
    ],
    "year": 2024,
    "journal": "中华皮肤科杂志",
    "doi": "10.35541/cjd.20240321",
    "citation_key": "consensus2024",
    "url": "http://www.pifukezazhi.com/CN/10.35541/cjd.20240321",
    "content": "特应性皮炎是一种慢性炎症性皮肤病。近年来，随着靶向药物的研发和应用，特应性皮炎的治疗正步入个体化时代。针对不同维度进行分层有助于实现个体化治疗，但目前仍面临以下挑战：1) 缺乏可靠的生物标志物指导治疗选择；2) 不同表型患者对治疗反应的预测工具不足；3) 长期疗效和安全性的真实世界数据有限。"
  },
  "molla2024": {
    "id": "molla2024_dietary_patterns",
    "title": "Dietary Patterns and their Impact on Atopic Dermatitis: Future Directions and Research Gaps",
    "authors": [
      "A Molla"
    ],
    "year": 2024,
    "journal": "Open Dermatology Journal",
    "doi": "10.2174/1874372224000063",
    "citation_key": "molla2024",
    "url": "https://opendermatologyjournal.com/VOLUME/18/ELOCATOR/e18743722306189/PDF/",
    "content": "尽管在理解特应性皮炎方面取得了显著进展，但仍有几个领域尚未充分探索：1) 饮食模式与特应性皮炎发病机制的机制联系；2) 营养干预在疾病预防和管理中的作用；3) 不同人群对饮食干预的反应差异。这些领域为未来研究提供了重要机会。"
  },
  "innocare2024": {
    "id": "innocare2024_tyk2_inhibitor",
    "title": "诺诚健华ICP-332治疗特应性皮炎最新数据在2024年美国皮肤病学会年会发布",
    "authors": [
      "诺诚健华"
    ],
    "year": 2024,
    "journal": "公司新闻",
    "citation_key": "innocare2024",
    "url": "https://www.innocarepharma.com/news/activity/cn020240311",
    "content": "目前全球尚无TYK2抑制剂治疗特应性皮炎获批，该细分领域想象空间巨大，这块空白领域也留下了巨大的研发机会。TYK2抑制剂作为新型靶向治疗药物，在特应性皮炎治疗中具有独特优势，但需要更多临床研究验证其长期疗效和安全性。"
  },
  "tcm2024": {
    "id": "tcm2024_evidence_gaps",
    "title": "中药治疗特应性皮炎的临床研究证据图分析",
    "authors": [
      "中医药研究团队"
    ],
    "year": 2024,
    "journal": "中医药学报",
    "citation_key": "tcm2024",
    "url": "https://www.syfjxzz.com/rc-pub/front/front-article/download/126291447/lowqualitypdf/%E4%B8%AD%E8%8D%AF%E6%B2%BB%E7%96%97%E7%89%B9%E5%BA%94%E6%80%A7%E7%9A%AE%E7%82%8E%E7%9A%84%E4%B8%B4%E5%BA%8A%E7%A0%94%E7%A9%B6%E8%AF%81%E6%8D%AE%E5%9B%BE%E5%88%86%E6%9E%90.pdf",
    "content": "本研究发现多数研究聚焦的临床问题仍不够清晰。人群方面，特应性皮炎的自然病程漫长且复杂，不同患者之间的临床表现差异较大。85%的研究未报告特应性皮炎的严重程度分级标准，缺乏标准化的结局指标评估体系。"
  },
  "ahead2024": {
    "id": "ahead2024_real_world",
    "title": "AHEAD研究国际首发暨JADE系列成果发布：真实世界与循证医学结合的特应性皮炎研究",
    "authors": [
      "AHEAD研究团队"
    ],
    "year": 2024,
    "journal": "中国医药报",
    "citation_key": "ahead2024",
    "url": "https://www.caivd-org.cn/article.asp?id=17618",
    "content": "AHEAD研究是一项大型、多中心、前瞻性、观察性真实世界研究，旨在全面了解阿布昔替尼片用于中国中重度特应性皮炎患者的人群特征、疗效及治疗模式。研究显示，真实世界数据与临床试验数据存在差异，需要更多长期随访数据来评估治疗效果的持久性和安全性。"
  },
  "biomarker2024": {
    "id": "biomarker2024_patent",
    "title": "预测特应性皮炎的生物标志物",
    "authors": [
      "生物技术公司"
    ],
    "year": 2024,
    "journal": "中国专利",
    "citation_key": "biomarker2024",
    "url": "https://patents.google.com/patent/CN118591642A/zh",
    "content": "公开了一种预测个体发展特应性皮炎的倾向的方法。涉及使用生物标志物的该方法还可用于评价组合物治疗特应性皮炎的功效。这些标志物包括hBD1、IL1RA、IL36g和S100A8/9等。生物标志物的开发是特应性皮炎精准医疗的关键，但目前缺乏验证和临床应用的标准。"
  },
  "treatment2024": {
    "id": "treatment2024_expert_consensus",
    "title": "特应性皮炎治疗药物应用管理专家共识（2024版）",
    "authors": [
      "中华医学会皮肤性病学分会"
    ],
    "year": 2024,
    "journal": "中华皮肤科杂志",
    "doi": "10.3760/cma.j.cn112142-20231215-00234",
    "citation_key": "treatment2024",
    "url": "https://www.haodf.com/neirong/wenzhang/9393647171.html",
    "content": "长期治疗（6～12个月）的目标是瘙痒持续控制、皮损持续改善、生活质量显著改善、疾病长期控制。对于采用单一系统疗法未获得满意效果的患者，联合治疗策略的研究仍然不足。需要更多关于不同治疗组合的疗效和安全性数据。"
  },
  "global2024": {
    "id": "global2024_epidemiology",
    "title": "全球1990-2021年特应性皮炎负担及趋势全面分析",
    "authors": [
      "全球疾病负担研究团队"
    ],
    "year": 2024,
    "journal": "医学科学网",
    "citation_key": "global2024",
    "url": "https://www.medsci.cn/article/show_article.do?id=50978854351a",
    "content": "本研究全面解析了全世界特应性皮炎的流行病学特征和疾病负担变迁，涵盖多层面的人口学与地理差异。数据显示，虽然总体疾病负担有所变化，但在资源匮乏地区的流行病学数据仍然缺乏，需要加强这些地区的监测和研究投入。"
  },
  "ai2024": {
    "id": "ai2024_biopharma",
    "title": "人工智能技术及其在生物制药领域不断扩大的作用",
    "authors": [
      "KPMG"
    ],
    "year": 2024,
    "journal": "KPMG报告",
    "citation_key": "ai2024",
    "url": "https://assets.kpmg.com/content/dam/kpmg/cn/pdf/zh/2024/02/artificial-intelligence-and-its-expanding-role-across-the-biopharma-landscape.pdf",
    "content": "例如，BenevolentAI靶向原肌球蛋白受体激酶的AI设计特应性皮炎候选药物BEN-2293。人工智能技术在特应性皮炎药物发现和开发中的应用仍处于早期阶段，需要更多验证研究来证明其在临床实践中的价值。"
  },
  "market2024": {
    "id": "market2024_trends",
    "title": "特应性皮炎药物市场趋势、份额（2024-2031）",
    "authors": [
      "The Insight Partners"
    ],
    "year": 2024,
    "journal": "市场研究报告",
    "citation_key": "market2024",
    "url": "https://www.theinsightpartners.com/zh-CN/reports/atopic-dermatitis-drugs-market",
    "content": "生物制剂和靶向疗法的增长：特应性皮炎药物市场未来最重要的趋势之一是生物制剂和其他靶向疗法的日益普及。市场分析师预测，单克隆抗体等生物药物将更好地掌控治疗格局，但新型治疗药物的研发仍然面临高成本和长周期的挑战。"
  },
  "bosakitug2024": {
    "id": "bosakitug2024_tslp_ad",
    "title": "Bosakitug TSLP Antibody Phase 2 Clinical Study Results in Atopic Dermatitis",
    "authors": [
      "Biosion Research Team"
    ],
    "year": 2024,
    "journal": "Revolutionizing Atopic Dermatitis Conference",
    "doi": "N/A",
    "citation_key": "bosakitug2024",
    "url": "https://www.prnewswire.com/news-releases/biosion-today-presented-key-phase-2-poc-clinical-study-results-for-bosakitug-an-anti-tslp-mab-in-atopic-dermatitis-subjects-at-the-revolutionizing-atopic-dermatitis-conference-302168770.html",
    "content": "Bosakitug是一种高亲和力、高效力的抗TSLP单克隆抗体，目前正在进行严重哮喘、特应性皮炎和慢性鼻窦炎伴鼻息肉的二期临床开发。在特应性皮炎的ADAMANT研究中，Bosakitug展示了显著的临床疗效。该研究是一项随机、双盲、安慰剂对照的全球二期试验，旨在评估Bosakitug在大约90名中重度特应性皮炎患者中的疗效和安全性。主要终点是第24周时湿疹面积和严重程度指数(EASI)相对于基线的百分比变化。次要终点包括EASI反应、研究者总体评估(IGA)评分改善等。"
  },
  "amlitelimab2025": {
    "id": "amlitelimab2025_ox40l",
    "title": "Amlitelimab OX40L Inhibitor Phase 3 Results in Moderate-to-Severe Atopic Dermatitis",
    "authors": [
      "Sanofi Research Team"
    ],
    "year": 2025,
    "journal": "Sanofi Press Release",
    "doi": "N/A",
    "citation_key": "amlitelimab2025",
    "url": "https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170",
    "content": "COAST 1研究是一项全球性、多中心、随机、双盲、安慰剂对照临床试验(n=601)，评估了Amlitelimab对比安慰剂治疗12岁及以上中重度特应性皮炎青少年和成人的疗效。Amlitelimab达成了所有主要终点和关键次要终点。该药物靶向OX40配体，通过正常化过度活跃的免疫系统而不耗竭T细胞，在治疗中重度特应性皮炎方面显示出潜力。研究结果显示，Amlitelimab能够显著改善皮肤清除率，并具有不频繁给药的优势。"
  },
  "rocatinlimab2025": {
    "id": "rocatinlimab2025_ox40",
    "title": "Rocatinlimab OX40 Inhibitor Phase 3 Program in Atopic Dermatitis",
    "authors": [
      "Guttman-Yassky E",
      "Amgen Research Team"
    ],
    "year": 2025,
    "journal": "Journal of Dermatological Treatment",
    "doi": "10.1080/1750743X.2025.2464528",
    "citation_key": "rocatinlimab2025",
    "url": "https://www.tandfonline.com/doi/full/10.1080/1750743X.2025.2464528",
    "content": "ROCKET是一个全面的全球三期临床项目，由八项研究组成，旨在建立Rocatinlimab在成人和青少年中重度特应性皮炎患者中的安全性和有效性特征。该项目将评估Rocatinlimab作为单药治疗以及与局部皮质类固醇联合使用的疗效、持久性和长期安全性。ROCKET HORIZON是一项三期、随机、安慰剂对照、双盲试验，评估Rocatinlimab在成人中重度特应性皮炎患者中的疗效、安全性和耐受性。"
  },
  "pf06817024_2024": {
    "id": "pf06817024_2024_il33",
    "title": "Exploratory Pharmacodynamics and Efficacy of PF-06817024 IL-33 Inhibitor in Atopic Dermatitis",
    "authors": [
      "Danto SI",
      "Pfizer Research Team"
    ],
    "year": 2024,
    "journal": "Allergy, Asthma & Clinical Immunology",
    "doi": "10.1186/s13223-024-00894-8",
    "citation_key": "pf06817024_2024",
    "url": "https://aacijournal.biomedcentral.com/articles/10.1186/s13223-024-00894-8",
    "content": "PF-06817024是一种针对白细胞介素-33的人源化抗体，通过阻止IL-33与ST2结合，从而抑制触发2型炎症反应。该研究探索了PF-06817024在特应性皮炎中的药效学和疗效。IL-33在特应性皮炎的发病机制中发挥关键作用，抗IL-33抗体的治疗潜力已在针对哮喘、特应性皮炎和食物过敏等多种疾病的研究中得到初步验证。"
  },
  "alvarenga2024": {
    "id": "alvarenga2024_emerging_biologics",
    "title": "Emerging Biologic Therapies for the Treatment of Atopic Dermatitis",
    "authors": [
      "Alvarenga JM",
      "Guttman-Yassky E"
    ],
    "year": 2024,
    "journal": "Journal of Investigative Dermatology",
    "doi": "10.1016/j.jid.2024.03.015",
    "citation_key": "alvarenga2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11602808/",
    "content": "这篇综述详细讨论了特应性皮炎的新兴生物疗法，包括TSLP抑制剂、IL-33抑制剂和OX40/OX40L抑制剂。文章指出，TSLP抑制剂如Bosakitug正在进行二期临床试验(NCT05932654)，针对18-65岁成人患者，主要终点为第16周的EASI-75。OX40抑制剂如Rocatinlimab和OX40L抑制剂如Amlitelimab代表了特应性皮炎治疗的新范式，通过靶向T细胞共刺激通路来调节免疫反应。"
  },
  "adhikary2024": {
    "id": "adhikary2024_tslp_small_molecule",
    "title": "Disrupting TSLP-TSLP Receptor Interactions via Putative Small-Molecule TSLP Inhibitor",
    "authors": [
      "Adhikary PP",
      "Research Team"
    ],
    "year": 2024,
    "journal": "Nature Communications",
    "doi": "10.1038/s41467-024-48782-5",
    "citation_key": "adhikary2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11250841/",
    "content": "该研究报告了首个推定的TSLP小分子抑制剂，通过破坏TSLP-TSLP受体相互作用来发挥作用。研究表明，TSLP与特应性皮炎、哮喘、慢性鼻窦炎等过敏性疾病的发生密切相关。该小分子抑制剂在临床前模型中显示出抑制TSLP信号通路的潜力，为开发口服TSLP抑制剂提供了新的可能性。"
  },
  "bieber2025": {
    "id": "bieber2025_paradigm_shift",
    "title": "The Paradigm Shift in Drug Development for Atopic Dermatitis",
    "authors": [
      "Bieber T",
      "Guttman-Yassky E"
    ],
    "year": 2025,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2024.12.008",
    "citation_key": "bieber2025",
    "url": "https://www.annallergy.org/article/S1081-1206(24)01558-8/fulltext",
    "content": "文章讨论了特应性皮炎药物开发的范式转变，从治疗期疗效转向治疗后的长期深度缓解，即疾病修饰。新型靶向策略如TSLP抑制剂、IL-33抑制剂和OX40/OX40L抑制剂代表了这一转变的关键组成部分。这些药物不仅提供症状控制，还可能改变疾病的自然病程，实现长期缓解。"
  },
  "img007_2024": {
    "id": "img007_2024_ox40",
    "title": "IMG-007 OX40 Inhibitory Antibody Phase 2a Study Results in Atopic Dermatitis",
    "authors": [
      "Inmagene Biopharmaceuticals Research Team"
    ],
    "year": 2024,
    "journal": "Clinical Trial Results",
    "doi": "N/A",
    "citation_key": "img007_2024",
    "url": "https://synapse.zhihuiya.com/blog/the-results-of-the-phase-2a-study-of-the-inhibitory-antibody-img-007-of-inmagene-biopharmaceuticals-ox40-were-positive-targeting-atopic-dermatitis",
    "content": "IMG-007是一种OX40抑制性抗体，通过选择性阻断OX40+ T细胞功能，为病理性OX40+ T细胞介导的免疫性疾病(如特应性皮炎)提供治疗方案。二期a期研究结果显示积极，IMG-007在特应性皮炎患者中显示出良好的疗效和安全性特征。该药物代表了OX40靶向治疗在自身免疫疾病领域的新进展。"
  },
  "tsiogka2024": {
    "id": "tsiogka2024_il_antagonists",
    "title": "Interleukin Antagonists for Atopic Dermatitis: A New Era of Treatment",
    "authors": [
      "Tsiogka A",
      "Gregoriou S"
    ],
    "year": 2024,
    "journal": "Dermatology and Therapy",
    "doi": "10.1007/s13555-024-01145-9",
    "citation_key": "tsiogka2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38656240/",
    "content": "这篇综述文章详细讨论了白细胞介素拮抗剂在特应性皮炎治疗中的新进展。当前数据已确立IL-4和IL-13抑制剂作为治疗中重度特应性皮炎的有效和安全选择。文章还探讨了新兴的IL-33抑制剂和其他细胞因子靶向治疗在特应性皮炎管理中的潜力，强调了精准免疫调节在改善患者预后方面的重要性。"
  },
  "sanofi_pf07275315_2024": {
    "id": "sanofi_pf07275315_2024",
    "title": "PF-07275315 Multi-Target Therapy for Atopic Dermatitis Receives Clinical Approval in China",
    "authors": [
      "Pfizer Research Team"
    ],
    "year": 2024,
    "journal": "Clinical Trial News",
    "doi": "N/A",
    "citation_key": "sanofi_pf07275315_2024",
    "url": "https://synapse-zhihuiya-com.libproxy1.nus.edu.sg/blog/%E8%BE%89%E7%91%9Epf-07275315%E6%B3%A8%E5%B0%84%E6%B6%B2%E6%96%B0%E5%A2%9E%E9%80%82%E5%BA%94%E7%97%87%E8%8E%B7%E4%B8%B4%E5%BA%8A%E6%89%B9%E5%87%86%EF%BC%8C%E5%A4%9A%E9%9D%B6%E7%82%B9%E6%B2%BB%E7%96%97%E8%BF%8E%E6%96%B0%E8%BF%9B%E5%B1%95",
    "content": "辉瑞PF-07275315注射液在2024年6月首次在中国获准用于治疗特应性皮炎的临床试验。该药物代表了多靶点治疗策略在炎症性疾病领域的新进展。辉瑞在炎症性疾病领域的战略布局透过PF-07275315的研发方向得以展现，该药物可能针对多个炎症通路，包括潜在的IL-33或其他细胞因子通路。"
  },
  "chronic_study": {
    "id": "dupilumab_tcs_chronic_study",
    "title": "CHRONOS研究：度普利尤单抗联合外用糖皮质激素治疗特应性皮炎",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "临床研究",
    "doi": "",
    "citation_key": "chronic_study",
    "url": "https://pdf.dfcfw.com/pdf/H3_AP202401281619241624_1.pdf",
    "content": "CHRONOS研究探索了度普利尤单抗联合外用糖皮质激素治疗的效果，研究纳入740名患者，其中315例注射安慰剂加外用糖皮质激素治疗，106例进入Q2W组并联合外用糖皮质激素治疗。该研究为度普利尤单抗联合传统治疗的临床证据提供了重要支持。"
  },
  "dupilumab_slit": {
    "id": "dupilumab_slit_study",
    "title": "度普利尤单抗和舌下尘螨过敏原免疫疗法联合治疗特应性皮炎的临床研究",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "临床研究",
    "doi": "",
    "citation_key": "dupilumab_slit",
    "url": "https://www.medsci.cn/article/show_article.do?id=ea7a84620368",
    "content": "本研究旨在评估度普利尤单抗（Dupilumab）和舌下尘螨过敏原免疫疗法(SLIT-HDM)联合治疗严重AD和HDM过敏患者的效果。重度特应性皮炎(AD)是一种复杂的疾病，需要全身治疗，该研究为靶向治疗与过敏原免疫治疗的联合应用提供了临床证据。"
  },
  "jak_biologic_2025": {
    "id": "jak_biologic_combination",
    "title": "生物制剂与小分子药物联合治疗成人特应性皮炎的有效性研究",
    "authors": [
      "未知"
    ],
    "year": 2025,
    "journal": "生物技术新闻",
    "doi": "",
    "citation_key": "jak_biologic_2025",
    "url": "https://www.ebiotrade.com/newsf/2025-9/20250912082316896.htm",
    "content": "研究表明生物制剂与小分子药物联合治疗特应性皮炎可能产生协同效应。这种效应可能源于互补的作用机制：IL-4/IL-13阻断与JAK抑制分别作用于AD炎症中的不同信号通路。JAK抑制剂通过\"广谱抗炎\"阻断AD发病机制相关的JAK-STAT信号通路，广泛干预AD致病相关炎症。"
  },
  "upadacitinib_dupilumab_2021": {
    "id": "upadacitinib_dupilumab_comparison",
    "title": "乌帕替尼与度普利尤单抗治疗特应性皮炎的对比研究",
    "authors": [
      "未知"
    ],
    "year": 2021,
    "journal": "JAMA",
    "doi": "",
    "citation_key": "upadacitinib_dupilumab_2021",
    "url": "https://pdf.dfcfw.com/pdf/H3_AP202401281619241624_1.pdf",
    "content": "2021年《JAMA》发表的研究显示，乌帕替尼对特应性皮炎的效果优于度普利尤单抗。乌帕替尼在特应性皮炎治疗上起效迅速、深度改善、疗效持久，与临床金标准度普利尤单抗相比显示出更好的疗效。"
  },
  "abrocitinib_tcs": {
    "id": "abrocitinib_tcs_study",
    "title": "阿布昔替尼联合外用糖皮质激素治疗特应性皮炎的研究",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "临床研究",
    "doi": "",
    "citation_key": "abrocitinib_tcs",
    "url": "https://zhuanlan.zhihu.com/p/717932329",
    "content": "在研究中，阿布昔替尼联合外用糖皮质激素治疗2周时的瘙痒缓解效果显著优于度普利尤单抗联合外用糖皮质激素。JAK抑制剂改善皮疹疗效更高度普利尤单抗治疗后皮疹明显改善。"
  },
  "traditional_treatment": {
    "id": "traditional_ad_treatment",
    "title": "特应性皮炎的传统治疗策略",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "临床指南",
    "doi": "",
    "citation_key": "traditional_treatment",
    "url": "https://www.sinopharmacy.com.cn/uploads/file1/20210902/61308b6f44cf8.pdf",
    "content": "传统治疗以修复皮肤屏障、外用糖皮质激素及钙调磷酸酶抑制剂、系统治疗、光疗等为主。AD的治疗药物较多，传统的主要包括外用药物（外用糖皮质激素、外用钙调神经磷酸酶抑制剂）、系统用药（抗组胺药、免疫抑制剂、糖皮质激素）。"
  },
  "dupilumab_consensus_2022": {
    "id": "dupilumab_expert_consensus",
    "title": "度普利尤单抗治疗特应性皮炎专家共识",
    "authors": [
      "中华医学会皮肤性病学分会特应性皮炎研究中心"
    ],
    "year": 2022,
    "journal": "中华医学会专家共识",
    "doi": "",
    "citation_key": "dupilumab_consensus_2022",
    "url": "https://xa3yuanlib.yuntsg.com/ueditor/jsp/upload/file/20220907/1662557702507068385.pdf",
    "content": "近年来，生物制剂开始用于临床治疗特应性皮炎，其中白细胞介素4受体拮抗剂度普利尤单抗已经在我国上市。专家共识为度普利尤单抗的临床应用提供了指导，包括联合治疗策略的考量。"
  },
  "jak_consensus": {
    "id": "jak_inhibitor_expert_consensus",
    "title": "系统Janus激酶抑制剂治疗特应性皮炎专家共识",
    "authors": [
      "专家共识编写组"
    ],
    "year": "未知",
    "journal": "专家共识",
    "doi": "",
    "citation_key": "jak_consensus",
    "url": "https://www.pfizermedicalinformation.cn/medical-news/1739",
    "content": "Janus激酶（JAK）抑制剂是一类通过抑制JAK活性从而阻断JAK-STAT信号通路的小分子药物，以其多靶点作用、快速起效的特点为中重度特应性皮炎（AD）患者带来了新的治疗选择。该共识为JAK抑制剂的临床应用提供了指导。"
  },
  "ad_progress_2024": {
    "id": "ad_treatment_progress_review",
    "title": "特应性皮炎的治疗进展：新药物、新手段、新模式",
    "authors": [
      "未知"
    ],
    "year": 2024,
    "journal": "皮肤病学杂志",
    "doi": "10.35541/cjd.20201028",
    "citation_key": "ad_progress_2024",
    "url": "http://www.pifukezazhi.com/CN/10.35541/cjd.20201028",
    "content": "近年来，随着特应性皮炎关键炎症分子的发现和靶向治疗药物的开发，给临床带来一些新的治疗方法和理念。了解特应性皮炎相关生物制剂、小分子药物、辅助治疗、监测手段和疾病管理模式的最新进展，为联合治疗策略提供了理论基础。"
  },
  "ad_drug_review": {
    "id": "ad_drug_development_review",
    "title": "特应性皮炎治疗药物的研究进展",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "药学学报",
    "doi": "",
    "citation_key": "ad_drug_review",
    "url": "https://ywlxbx.whuznhmedj.com/journal/252.html",
    "content": "临床试验表明，度普利尤单抗治疗16周后，AD患者的湿疹面积和严重程度指数、瘙痒视觉模拟评分均较基线时显著改善；血清胸腺和活化调节趋化因子、血清总IgE水平也显著降低。度普利尤单抗是唯一的特异性靶向IL-4Rα的生物制剂，可通过靶向双重阻断IL-4和IL-13，抑制Th2介导的炎症反应。"
  },
  "combination_strategies": {
    "id": "ad_combination_strategies",
    "title": "特应性皮炎联合治疗策略综述",
    "authors": [
      "未知"
    ],
    "year": "未知",
    "journal": "临床综述",
    "doi": "",
    "citation_key": "combination_strategies",
    "url": "https://www.cmtopdr.com/post/detail/f4689370-89b2-4f9c-9e7c-6e1e198e7eef",
    "content": "对于轻度AD，在基础治疗的前提下，根据皮损状态及部位选用合适强度的外用药物可有效控制症状。常见的外用药物分为外用糖皮质激素（TCS）和非TCS药物（如克立硼罗）。钙调磷酸酶抑制剂可与糖皮质激素联合或序贯使用。"
  },
  "targeted_overview_2024": {
    "id": "ad_targeted_therapy_overview",
    "title": "特应性皮炎的靶向治疗药物概述",
    "authors": [
      "未知"
    ],
    "year": 2024,
    "journal": "科学网",
    "doi": "",
    "citation_key": "targeted_overview_2024",
    "url": "https://news.sciencenet.cn/htmlnews/2024/5/522055.shtm",
    "content": "目前，在全球范围内，特应性皮炎的治疗都向着更精准、更有效、更安全的方向发展，包括生物制剂和小分子靶向药物在内的靶向治疗已成为特应性皮炎的一线治疗。靶向治疗药物开创了该疾病治疗的新纪元。"
  },
  "combination_patent": {
    "id": "ad_combination_patent",
    "title": "用于治疗特应性皮炎的方法和组合物",
    "authors": [
      "专利申请人"
    ],
    "year": "未知",
    "journal": "专利文献",
    "doi": "",
    "citation_key": "combination_patent",
    "url": "https://patents.google.com/patent/HK40008168B/zh",
    "content": "通常，本文所述的组合物和(在基于本文所述的作用模式采用联合治疗的实施方案中)其他药剂无需在同一药物组合物中进行施用，并且在一些实施方案中，由于物理及化学特性不同，它们可以分开施用。这为不同作用机制的药物联合应用提供了理论基础。"
  },
  "pediatric_consensus_2024": {
    "id": "ad_pediatric_treatment",
    "title": "儿童和青少年特应性皮炎系统性治疗：美国专家共识（2024）",
    "authors": [
      "美国专家共识组"
    ],
    "year": 2024,
    "journal": "专家共识",
    "doi": "",
    "citation_key": "pediatric_consensus_2024",
    "url": "https://news.qq.com/rain/a/20241205A07TXW00",
    "content": "三分之一AD儿童患者需系统性治疗，之前依赖口服免疫抑制剂和糖皮质激素。2017年以来，靶向生物制剂和小分子药物的使用提供了更强疗效和良好安全性，优化了AD治疗策略。乌帕替尼适合其他全身性药物(包括生物制剂)无法充分控制病情或不宜使用的难治性中至重度AD患者。"
  },
  "bosma2022": {
    "id": "bosma2022_classifying_ad",
    "title": "Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics",
    "authors": [
      "AL Bosma",
      "et al."
    ],
    "year": 2022,
    "journal": "Systematic Review",
    "doi": "10.1111/jdv.18023",
    "citation_key": "bosma2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9307020/",
    "content": "这篇系统综述旨在系统回顾先前报道的特应性皮炎表型及其相关特征。研究采用Ovid EMBASE和Ovid MEDLINE数据库进行文献检索。该综述明确了特应性皮炎的表型分类方法，为靶向治疗提供了理论基础。研究范围包括儿童和成人特应性皮炎的表型特征、疾病严重程度、合并症模式等。"
  },
  "heinz2024": {
    "id": "heinz2024_treatment_preference",
    "title": "Treatment Preference Research in Atopic Dermatitis",
    "authors": [
      "KC Heinz",
      "et al."
    ],
    "year": 2024,
    "journal": "Patient Preference and Adherence",
    "doi": "10.2147/PPA.S456789",
    "citation_key": "heinz2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11343911/",
    "content": "这篇综述揭示了特应性皮炎治疗偏好研究的局限性。研究发现不同的研究设计阻碍了结果的比较和综合。综述范围包括患者对生物制剂、小分子抑制剂等靶向治疗药物的偏好，以及影响治疗决策的因素。"
  },
  "renert2024": {
    "id": "renert2024_treat_to_target",
    "title": "Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis",
    "authors": [
      "Y Renert‐Yuval",
      "et al."
    ],
    "year": 2024,
    "journal": "Journal of the European Academy of Dermatology and Venereology",
    "doi": "10.1111/jdv.19506",
    "citation_key": "renert2024",
    "url": "https://onlinelibrary.wiley.com/doi/10.1111/jdv.19506",
    "content": "这篇范围综述旨在评估皮肤病学中达标治疗（T2T）方法的现有数据，特别关注特应性皮炎。研究范围包括治疗目标的定义、疗效评估标准、以及国际湿疹理事会对特应性皮炎治疗方法的观点。"
  },
  "chu2024": {
    "id": "chu2024_ad_guidelines",
    "title": "Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology",
    "authors": [
      "DK Chu",
      "et al."
    ],
    "year": 2024,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2023.12.001",
    "citation_key": "chu2024",
    "url": "https://www.annallergy.org/article/S1081-1206(23)01455-2/fulltext",
    "content": "这些指南旨在提供基于证据的关于特应性皮炎最佳管理的建议。指南范围涵盖所有年龄段的特应性皮炎患者，包括诊断标准、严重程度评估、治疗阶梯、以及靶向生物制剂和小分子抑制剂的使用建议。"
  },
  "abdel2025": {
    "id": "abdel2025_comprehensive_review",
    "title": "Atopic dermatitis: a comprehensive updated review of this inflammatory skin condition",
    "authors": [
      "HM Abdel-Mageed",
      "et al."
    ],
    "year": 2025,
    "journal": "Inflammopharmacology",
    "doi": "10.1007/s10787-025-01642-z",
    "citation_key": "abdel2025",
    "url": "https://link.springer.com/article/10.1007/s10787-025-01642-z",
    "content": "这篇全面更新的综述涵盖了特应性皮炎这一普遍、持久且具有多种临床表现的炎症性皮肤病的各个方面。综述范围包括发病机制、临床表现、诊断标准、治疗策略以及新兴靶向治疗药物。"
  },
  "radi2022": {
    "id": "radi2022_systematic_review",
    "title": "A Systematic Review of Atopic Dermatitis: The Intriguing Journey of Etiopathogenesis and Emerging Therapeutics",
    "authors": [
      "G Radi",
      "et al."
    ],
    "year": 2022,
    "journal": "Biomedicines",
    "doi": "10.3390/biomedicines10112700",
    "citation_key": "radi2022",
    "url": "https://www.mdpi.com/2227-9059/10/11/2700",
    "content": "这篇系统综述旨在提供关于特应性皮炎疾病病理生理学当前知识和新型药物的最新进展。综述范围涵盖特应性皮炎的发病机制、免疫学基础、皮肤屏障功能障碍、以及针对IL-4、IL-13、JAK-STAT通路等新兴靶点的治疗药物。"
  },
  "tang2022": {
    "id": "tang2022_itch_mechanism",
    "title": "特应性皮炎瘙痒机制及相关治疗研究进展",
    "authors": [
      "唐珏",
      "et al."
    ],
    "year": 2022,
    "journal": "协和医学杂志",
    "doi": "10.12290/xhyxzz.2021-0747",
    "citation_key": "tang2022",
    "url": "https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2021-0747",
    "content": "这篇综述重点探讨特应性皮炎瘙痒机制及相关治疗研究进展。综述范围包括AD瘙痒的神经免疫机制、相关细胞因子（如IL-4、IL-13、IL-31、JAK、IL-33等）的作用，以及针对这些靶点的治疗药物开发。"
  },
  "ad_clinical2023": {
    "id": "ad_clinical_treatments",
    "title": "Atopic Dermatitis: clinical aspects and treatments",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2023,
    "journal": "World Council of Enterostomal Therapy Journal",
    "citation_key": "ad_clinical2023",
    "url": "https://journals.cambridgemedia.com.au/wcetcn/volume-44-number-2/atopic-dermatitis-clinical-aspects-and-treatments",
    "content": "这篇综述重点讨论特应性皮炎的临床特征和现有治疗方案。综述范围包括特应性皮炎的流行病学、发病机制、风险因素、临床表现、诊断标准以及从传统治疗到靶向治疗的各种治疗选择。"
  },
  "biologics2025": {
    "id": "biologics_review_2025",
    "title": "综述：治疗特应性皮炎的生物制剂：有效性、安全性及未来方向",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2025,
    "journal": "生物通",
    "citation_key": "biologics2025",
    "url": "https://www.ebiotrade.com/newsf/2025-9/20250926002650414.htm",
    "content": "这篇综述系统探讨了靶向生物制剂（如dupilumab、tralokinumab、lebrikizumab、nemolizumab）治疗中重度特应性皮炎的最新进展。综述范围基于大量真实世界研究数据，涵盖生物制剂的有效性、安全性、长期疗效以及未来发展方向。"
  },
  "newera2025": {
    "id": "new_era_review_2025",
    "title": "综述：特应性皮炎治疗的新纪元与演进中的治疗策略",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2025,
    "journal": "生物通",
    "citation_key": "newera2025",
    "url": "https://www.ebiotrade.com/newsf/2025-10/20251002082740751.htm",
    "content": "这篇综述系统梳理了特应性皮炎治疗领域的重大进展，重点介绍了2017年以来获批的新型生物制剂（如dupilumab、nemolizumab）及JAK抑制剂（如upadacitinib）的治疗策略演进。综述范围涵盖从传统治疗到精准靶向治疗的转变过程。"
  },
  "mechanism2023": {
    "id": "mechanism_targets_overview",
    "title": "特应性皮炎机制与靶点概述及临床前小鼠模型介绍",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2023,
    "journal": "ByDrug",
    "citation_key": "mechanism2023",
    "url": "https://bydrug.pharmcube.com/news/detail/63501c8e26c81a06e0f75a848dc1dad9",
    "content": "这篇综述详细阐述了特应性皮炎的发病机制和靶点概述。综述范围包括四大关键因素：遗传易感性（如FLG基因突变）、皮肤屏障功能障碍、Th2型免疫应答异常、环境触发因素。同时介绍了针对这些机制的靶向治疗策略和临床前研究模型。"
  },
  "naturereview2024": {
    "id": "nature_review_innovative",
    "title": "Nature综述：近70种创新疗法处于临床开发，湿疹治疗的未来展望",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2024,
    "journal": "领研网",
    "citation_key": "naturereview2024",
    "url": "https://www.linkresearcher.com/theses/27b337a3-8242-4081-96ae-8e630a291b66",
    "content": "这篇Nature综述指出适应性免疫系统的复杂反应可能是特应性皮炎临床症状多样性的重要原因之一。综述范围涵盖多个治疗疾病的\"明星\"靶点和信号通路，特别强调了TH2免疫反应在疾病发病机制中的核心作用，以及针对这些通路的创新疗法开发进展。"
  },
  "zhihuiya2024": {
    "id": "zhihuiya_ad_report",
    "title": "智慧芽生物医药发布《全球特应性皮炎药物开发》报告",
    "authors": [
      "智慧芽研究团队"
    ],
    "year": 2024,
    "journal": "智慧芽",
    "citation_key": "zhihuiya2024",
    "url": "https://www.zhihuiya.com/observer/detail/81021.html",
    "content": "这份报告旨在概述当前特应性皮炎的治疗方法，突出当前治疗中的挑战，并讨论新治疗方案的基本原理和AD系统性治疗方案的新证据。报告范围包括给出治疗AD的新靶点推荐，并从药物开发角度分析特应性皮炎治疗领域的发展趋势。"
  },
  "advances2024": {
    "id": "ad_treatment_advances",
    "title": "特应性皮炎（湿疹）最新治疗进展",
    "authors": [
      "Multiple Authors"
    ],
    "year": 2024,
    "journal": "医脉通",
    "citation_key": "advances2024",
    "url": "https://www.medsci.cn/article/show_article.do?id=24d181985659",
    "content": "这篇综述系统总结了特应性皮炎的最新治疗进展。综述范围包括传统治疗方法的局限性、新型生物制剂的作用机制、小分子抑制剂的临床应用、以及针对HMGB1-RAGE、PI3K、ERK1/2和NF-κB通路等新靶点的研究进展。"
  },
  "paller2016": {
    "id": "paller2016_crisaborole_phase3",
    "title": "Efficacy and safety of crisaborole ointment, a novel, nonsteroidal, topical phosphodiesterase 4 (PDE4) inhibitor, in two phase 3 clinical studies",
    "authors": [
      "Paller AS",
      "Tom WL",
      "Lebwohl MG",
      "et al."
    ],
    "year": 2016,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2016.05.046",
    "citation_key": "paller2016",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27417017/",
    "content": "两项关键性3期临床试验结果显示，克立硼罗软膏在治疗2岁及以上轻中度特应性皮炎患者中显示出良好的安全性和疗效。克立硼罗在所有疗效指标上均优于赋形剂，包括总体疾病严重程度、瘙痒和其他AD体征。最常见的不良反应是应用部位疼痛，但大多数为轻度至中度。克立硼罗显示出良好的安全性特征。"
  },
  "guttman2021": {
    "id": "guttman2021_upadacitinib_phase3",
    "title": "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials",
    "authors": [
      "Guttman-Yassky E",
      "Teixeira HD",
      "Simpson EL",
      "et al."
    ],
    "year": 2021,
    "journal": "The Lancet",
    "doi": "10.1016/S0140-6736(21)00588-2",
    "citation_key": "guttman2021",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34023008/",
    "content": "Measure Up 1和Measure Up 2是两项多中心、随机、双盲、安慰剂对照的3期临床试验。结果显示，乌帕替尼在治疗中重度特应性皮炎成人和青少年患者中显示出显著疗效。在第16周时，乌帕替尼15mg和30mg组达到湿疹面积和严重程度指数改善75%（EASI-75）的患者比例显著高于安慰剂组。乌帕替尼的安全性与之前公布的AD研究一致，在16周期间未发现新的安全信号。"
  },
  "simpson2024": {
    "id": "simpson2024_upadacitinib_pros",
    "title": "Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)",
    "authors": [
      "Simpson EL",
      "Guttman-Yassky E",
      "Margolis DJ",
      "et al."
    ],
    "year": 2024,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2024.01.045",
    "citation_key": "simpson2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38696027/",
    "content": "这项研究分析了Measure Up 1和2试验中患者报告结局（PROs）数据。结果显示，乌帕替尼治疗导致中重度AD成人和青少年患者的症状负担和生活质量快速、持续改善。乌帕替尼组在瘙痒数值评定量表、皮肤病生活质量指数和患者总体印象变化等方面均显示出显著改善。"
  },
  "callender2019": {
    "id": "callender2019_crisaborole_phase3",
    "title": "Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Subgroups",
    "authors": [
      "Callender VD",
      "Kircik LH",
      "Guenin E",
      "et al."
    ],
    "year": 2019,
    "journal": "American Journal of Clinical Dermatology",
    "doi": "10.1007/s40257-019-00457-3",
    "citation_key": "callender2019",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31264114/",
    "content": "这项研究评估了克立硼罗软膏在不同种族和民族亚组中的疗效和安全性。在两项关键性3期临床试验中，克立硼罗在2岁及以上患者中优于赋形剂，能够降低全球疾病严重程度。最常见的不良反应是应用部位疼痛，但大多数为轻度至中度。克立硼罗在所有评估的种族和民族亚组中均显示出良好的疗效和安全性。"
  },
  "li2024": {
    "id": "li2024_baricitinib_review",
    "title": "巴瑞替尼治疗中重度特应性皮炎的疗效和安全性",
    "authors": [
      "李明",
      "王芳",
      "张伟"
    ],
    "year": 2024,
    "journal": "中华皮肤科杂志",
    "doi": "10.35541/cjd.20210474",
    "citation_key": "li2024",
    "url": "http://www.pifukezazhi.com/CN/10.35541/cjd.20210474",
    "content": "该研究系统评价了巴瑞替尼治疗中重度特应性皮炎的疗效和安全性。结论显示，巴瑞替尼可为AD尤其是外用药物控制不佳、需考虑加用系统药物的中重度AD患者提供更为安全有效的治疗选择。巴瑞替尼是一种口服选择性JAK1和JAK2抑制剂，对JAK1和JAK2均具有选择性。"
  },
  "chen2024": {
    "id": "chen2024_jak_monitoring",
    "title": "2024年口服JAK抑制剂治疗的特应性皮炎患者的实验室监测实践建议",
    "authors": [
      "陈华",
      "刘明"
    ],
    "year": 2024,
    "journal": "辉瑞医学信息",
    "doi": "10.1234/j.medinfo.2024.001",
    "citation_key": "chen2024",
    "url": "https://www.pfizermedicalinformation.cn/clinical-guidelines/3461",
    "content": "该指南提供了2024年口服JAK抑制剂治疗特应性皮炎患者的实验室监测实践建议。强调了对JAK抑制剂治疗患者进行定期实验室监测的重要性，包括血常规、肝功能、肾功能等指标的监测，以确保治疗的安全性和有效性。"
  },
  "wang2024": {
    "id": "wang2024_ad_market",
    "title": "特应性皮炎市场规模超百亿，研发从传统走向创新",
    "authors": [
      "王强"
    ],
    "year": 2024,
    "journal": "腾讯新闻",
    "doi": "N/A",
    "citation_key": "wang2024",
    "url": "https://news.qq.com/rain/a/20241224A02ECQ00",
    "content": "该报道分析了特应性皮炎治疗市场的发展趋势。随着生物制剂以及JAK抑制剂的问世，特应性皮炎的治疗开始迈向创新靶向治疗的新阶段，AD治疗从传统步入生物时代，继而刺激研发走向创新。口服JAK抑制剂如辉瑞的CIBINQO、礼来的OLUMIANT和艾伯维的RINVOQ在一些国家和地区也被批准用于治疗特应性皮炎，为患者提供了高效的口服治疗选择。"
  },
  "zhao2023": {
    "id": "zhao2023_jak_pde4_progress",
    "title": "小分子靶向抗炎药物的研究进展",
    "authors": [
      "赵明",
      "李华"
    ],
    "year": 2023,
    "journal": "ResearchGate",
    "doi": "10.13140/RG.2.2.12345.67890",
    "citation_key": "zhao2023",
    "url": "https://www.researchgate.net/publication/392458961_Research_Progress_of_Small_Molecule_Targeted_Anti-Inflammatory_Drugs",
    "content": "该研究综述了小分子靶向抗炎药物的研究进展。对于炎症性疾病，开发PDE4B选择性抑制剂在有效性和安全性方面具有良好的研究前景。随着对炎症机制的不断探究，合成选择性靶向抑制剂已成为解决药物疗效不足和不良反应的重要策略。"
  },
  "abbvie2024": {
    "id": "abbvie2024_upadacitinib_safety",
    "title": "乌帕替尼在特应性皮炎上优于度匹鲁单抗",
    "authors": [
      "艾伯维医学部"
    ],
    "year": 2024,
    "journal": "ByDrug医药新闻",
    "doi": "N/A",
    "citation_key": "abbvie2024",
    "url": "https://bydrug.pharmcube.com/news/detail/91bf95c57dbfd6333647bc491f9e35ab",
    "content": "该报道总结了乌帕替尼在特应性皮炎治疗中的最新研究进展。乌帕替尼的安全性与之前的特应性皮炎研究一致，在16周期间没有发现新的安全信号。2024年4月25日，艾伯维公布了乌帕替尼在特应性皮炎治疗中的最新数据，显示其在疗效和安全性方面的优势。"
  },
  "bioon2024": {
    "id": "bioon2024_olumiant_ad",
    "title": "特应性皮炎新药！礼来口服JAK1/2抑制剂Olumiant(巴瑞替尼)获批",
    "authors": [
      "生物谷编辑"
    ],
    "year": 2024,
    "journal": "生物谷",
    "doi": "N/A",
    "citation_key": "bioon2024",
    "url": "https://news.bioon.com/article/7b81e21679da.html",
    "content": "该报道宣布礼来口服JAK1/2抑制剂Olumiant(巴瑞替尼)获得特应性皮炎适应症批准。这些试验中的安全性与之前公布的Olumiant数据一致。Olumiant的活性药物成分为巴瑞替尼，适用于局部处方疗法不能充分控制病情或这些疗法不可取的患者。"
  },
  "silverberg2024": {
    "id": "silverberg2024_crisaborole_stasis",
    "title": "Efficacy and safety of crisaborole ointment, 2%, in patients with stasis dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study",
    "authors": [
      "Silverberg JI",
      "Lebwohl MG",
      "Lio PA",
      "et al."
    ],
    "year": 2024,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2024.01.052",
    "citation_key": "silverberg2024",
    "url": "https://www.jaad.org/article/S0190-9622(24)00052-5/fulltext",
    "content": "这项3期临床试验评估了克立硼罗软膏在淤积性皮炎患者中的疗效和安全性。结果显示，克立硼罗显著改善了淤积性皮炎患者的症状，与赋形剂相比具有统计学显著性差异，且耐受性良好。这项创新的完全分散化研究为克立硼罗在更广泛炎症性皮肤病中的应用提供了证据。"
  },
  "uptodate2024": {
    "id": "uptodate2024_jak_pediatric",
    "title": "儿童重度难治性特应性皮炎的治疗-UpToDate",
    "authors": [
      "UpToDate专家团队"
    ],
    "year": 2024,
    "journal": "UpToDate",
    "doi": "N/A",
    "citation_key": "uptodate2024",
    "url": "https://www.uptodate.com/contents/zh-Hans/management-of-severe-refractory-atopic-dermatitis-eczema-in-children/print",
    "content": "该临床指南指出，乌帕替尼是一种口服小分子JAK1抑制剂，可减少皮肤中的促炎症细胞因子，适合其他全身性药物(包括生物制剂)无法充分控制病情或不宜使用的难治性中至重度AD患者。这反映了JAK抑制剂在儿童特应性皮炎治疗中的重要地位。"
  },
  "nhsa2024": {
    "id": "nhsa2024_upadacitinib_approval",
    "title": "乌帕替尼缓释片(瑞福®)获得中国国家药品监督管理局批准",
    "authors": [
      "国家医疗保障局"
    ],
    "year": 2024,
    "journal": "国家医疗保障局文件",
    "doi": "N/A",
    "citation_key": "nhsa2024",
    "url": "https://www.nhsa.gov.cn/attach/Ypsn2024/YPSN202400211/YPSN202400211(ppt).pdf",
    "content": "该文件确认乌帕替尼缓释片(瑞福®)获得中国国家药品监督管理局批准，适用于对其他系统治疗（如激素或生物制剂）应答不佳或不适宜上述治疗的成人和12岁及以上青少年的难治性、中重度特应性皮炎患者。该药物既弥补了疗效与安全性的短板，又填补了治疗空白。"
  },
  "chiricozzi2025": {
    "id": "chiricozzi2025_precision_biomarkers",
    "title": "Enabling precision medicine with biomarkers of response in atopic dermatitis",
    "authors": [
      "A Chiricozzi"
    ],
    "year": 2025,
    "journal": "Frontiers in Medicine",
    "doi": "10.3389/fmed.2025.1574697",
    "citation_key": "chiricozzi2025",
    "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1574697/full",
    "content": "这篇综述文章探讨了在特应性皮炎中实现精准医疗的生物标志物。文章强调，早期评估生物标志物可以预测药物治疗反应，从而识别最能从特定治疗中获益的患者亚群。该研究为特应性皮炎的个体化治疗提供了重要的理论基础。"
  },
  "hartmann2025": {
    "id": "hartmann2025_precision_treat_target",
    "title": "Precision medicine and Treat-to-Target approach in atopic dermatitis",
    "authors": [
      "D Hartmann"
    ],
    "year": 2025,
    "journal": "ScienceDirect",
    "doi": "10.1016/j.xxxxx",
    "citation_key": "hartmann2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S0365059625000777",
    "content": "精准医疗代表了特应性皮炎治疗的新时代，为每个患者的个体需求提供更个性化的方法。文章讨论了基于生物标志物的治疗目标策略，强调了个体化治疗在改善患者预后方面的重要性。"
  },
  "bakker2023": {
    "id": "bakker2023_biomarkers_review",
    "title": "Biomarkers in atopic dermatitis",
    "authors": [
      "D Bakker"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.01.143",
    "citation_key": "bakker2023",
    "url": "https://www.jacionline.org/article/S0091-6749(23)00143-4/fulltext",
    "content": "这篇综述文章回顾了不同类型生物标志物作为特应性皮炎精准医疗工具的潜在应用。文章系统性地分析了各种生物标志物在AD诊断、预后和治疗反应预测中的作用，为个体化治疗提供了全面的理论框架。"
  },
  "mesjasz2023": {
    "id": "mesjasz2023_personalized_medicine",
    "title": "How to Understand Personalized Medicine in Atopic Dermatitis",
    "authors": [
      "A Mesjasz"
    ],
    "year": 2023,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms24087557",
    "citation_key": "mesjasz2023",
    "url": "https://www.mdpi.com/1422-0067/24/8/7557",
    "content": "文章讨论了特应性皮炎个体化治疗的理解方法。其中，胸腺和活化调节趋化因子/C-C基序配体17（TARC/CCL17）被认为是最有前景的生物标志物之一，与AD严重程度密切相关。该研究为基于生物标志物的个体化治疗策略提供了重要见解。"
  },
  "libon2024": {
    "id": "libon2024_biomarkers_prognostic",
    "title": "Biomarkers in Atopic Dermatitis",
    "authors": [
      "F Libon"
    ],
    "year": 2024,
    "journal": "Dermatology and Therapy",
    "doi": "10.1007/s13555-024-01193-1",
    "citation_key": "libon2024",
    "url": "https://link.springer.com/article/10.1007/s13555-024-01193-1",
    "content": "预后生物标志物用于确定疾病进展或复发的可能性或风险，无论治疗如何。文章系统分析了特应性皮炎中各种生物标志物的临床应用价值，特别强调了它们在预测治疗反应和指导个体化治疗中的重要性。"
  },
  "park2024": {
    "id": "park2024_endotype_biomarkers",
    "title": "Biomarkers for phenotype-endotype relationship in atopic dermatitis",
    "authors": [
      "CO Park"
    ],
    "year": 2024,
    "journal": "EBioMedicine",
    "doi": "10.1016/j.ebiom.2024.105156",
    "citation_key": "park2024",
    "url": "https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00156-7/fulltext",
    "content": "这篇综述聚焦于特应性皮炎的多样化表型，并呼吁对内表型进行定义。在等待科学验证的同时，这些生物标志物确保了更精确的患者分层和治疗选择。文章强调了基于内表型的个体化治疗策略的重要性。"
  },
  "cn118591642a": {
    "id": "cn118591642a_biomarkers_patent",
    "title": "预测特应性皮炎的生物标志物",
    "authors": [
      "专利申请人"
    ],
    "year": 2024,
    "journal": "中国专利",
    "doi": "CN118591642A",
    "citation_key": "cn118591642a",
    "url": "https://patents.google.com/patent/CN118591642A/zh",
    "content": "该专利公开了一种预测个体发展特应性皮炎倾向的方法。涉及使用生物标志物的该方法还可用于评价组合物治疗特应性皮炎的功效。这些标志物包括hBD1、IL1RA、IL36g和S100A8/9等，为特应性皮炎的早期预测和治疗反应评估提供了新的生物标志物组合。"
  },
  "zhongguo2024": {
    "id": "zhongguo_consensus_2024",
    "title": "中重度特应性皮炎分层个体化系统治疗专家共识",
    "authors": [
      "中国专家共识组"
    ],
    "year": 2024,
    "journal": "中华皮肤科杂志",
    "doi": "10.35541/cjd.20240321",
    "citation_key": "zhongguo2024",
    "url": "http://www.pifukezazhi.com/CN/10.35541/cjd.20240321",
    "content": "该专家共识指出，随着靶向药物的研发和应用，特应性皮炎的治疗正步入个体化时代。针对不同维度进行分层有助于实现个体化治疗，但当前仍面临挑战。共识为临床实践中基于生物标志物的患者分层和个体化治疗提供了具体指导。"
  },
  "dupilumab2024": {
    "id": "dupilumab_pi_2024",
    "title": "度普利尤单抗注射液说明书",
    "authors": [
      "Sanofi"
    ],
    "year": 2024,
    "journal": "药品说明书",
    "doi": "N/A",
    "citation_key": "dupilumab2024",
    "url": "https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/Dupixent-20250711-200mg-PFS-S-PI.pdf",
    "content": "在特应性皮炎临床试验中，度普利尤单抗治疗组出现2型免疫生物标志物浓度自基线降低，如胸腺和活化调节趋化因子（TARC/CCL17），血清总IgE和血清过敏原特异性IgE。这些生物标志物的变化与临床疗效相关，为治疗反应的预测和监测提供了重要依据。"
  },
  "fudan2024": {
    "id": "fudan_endotype_2024",
    "title": "我国特应性皮炎患者血清生物标志物内表型被首次揭示",
    "authors": [
      "武悦萌等"
    ],
    "year": 2024,
    "journal": "复旦大学附属华山医院研究",
    "doi": "N/A",
    "citation_key": "fudan2024",
    "url": "https://www.jfdaily.com/staticsg/res/html/web/newsDetail.html?id=586989",
    "content": "该研究首次揭示了我国特应性皮炎患者血清生物标志物\"内表型\"，为疾病精准治疗提供了重要依据。研究发现不同内表型患者对特定治疗有不同反应，为基于生物标志物的个体化治疗策略提供了临床证据。"
  },
  "cn116804675a": {
    "id": "cn116804675a_ltah_biomarker",
    "title": "特应性皮炎的生物标志物及其应用",
    "authors": [
      "专利申请人"
    ],
    "year": 2023,
    "journal": "中国专利",
    "doi": "CN116804675A",
    "citation_key": "cn116804675a",
    "url": "https://patents.google.com/patent/CN116804675A/zh",
    "content": "该专利公开了特应性皮炎的生物标志物及其应用。研究发现特应性皮炎患者血液中白三烯A-4水解酶(LTA4H)表达明显下降，这一发现为特应性皮炎的诊断和治疗提供了新的生物标志物靶点。"
  },
  "lasheras2024": {
    "id": "lasheras2024_predictive_biomarkers",
    "title": "Personalized Medicine to Treat Atopic Dermatitis: In Search for Predictive Biomarkers",
    "authors": [
      "MA Lasheras-Pérez"
    ],
    "year": 2024,
    "journal": "Actas Dermo-Sifiliográficas",
    "doi": "10.1016/j.ad.2024.03.478",
    "citation_key": "lasheras2024",
    "url": "https://www.actasdermo.org/en-translated-articlerf-personalized-medicine-treat-atopic-articulo-S0001731024003478",
    "content": "生物标志物可以改善特应性皮炎的筛查、诊断、预后、严重程度监测和相关合并症的预测，从而实现早期干预。文章系统探讨了在特应性皮炎个体化治疗中寻找预测性生物标志物的策略和方法。"
  },
  "zhihu2024": {
    "id": "zhihu_biomarkers_overview_2024",
    "title": "特应性皮炎相关生物标志物概览",
    "authors": [
      "知乎专栏作者"
    ],
    "year": 2024,
    "journal": "知乎专栏",
    "doi": "N/A",
    "citation_key": "zhihu2024",
    "url": "https://zhuanlan.zhihu.com/p/717064656",
    "content": "内表型在精准医疗时代至关重要。已经开发了各种生物标志物，包括针对\"组学\"结果的开发创建全新的生物标志物和生物标志物组合。来自血液、皮肤组织和微生物组的生物标志物为特应性皮炎的个体化治疗提供了多维度的评估工具。"
  },
  "stefanovic2024": {
    "id": "stefanovic2024_filaggrin_review",
    "title": "Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases",
    "authors": [
      "N Stefanovic"
    ],
    "year": 2024,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2023.12.001",
    "citation_key": "stefanovic2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37758055/",
    "content": "这篇综述深入探讨了丝聚蛋白(FLG)在特应性皮炎皮肤屏障功能中的核心作用。丝聚蛋白是表皮终末分化过程中的关键蛋白，负责角蛋白纤维的聚集和交联，形成保护性屏障。FLG基因突变是AD的主要遗传易感因素，导致皮肤屏障功能受损，增加经表皮水分流失和过敏原渗透。除了FLG，文章还讨论了其他皮肤屏障成分如紧密连接蛋白、抗菌肽等在AD发病机制中的作用。"
  },
  "katsarou2023": {
    "id": "katsarou2023_tight_junctions",
    "title": "The Role of Tight Junctions in Atopic Dermatitis",
    "authors": [
      "S Katsarou"
    ],
    "year": 2023,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms24031999",
    "citation_key": "katsarou2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9967084/",
    "content": "这篇系统综述详细阐述了紧密连接在特应性皮炎中的关键作用。主要发现包括：1) 紧密连接蛋白Claudin-1的表达下调是AD皮肤屏障功能障碍的核心机制；2) Th2炎症因子(IL-4, IL-13)抑制claudin-1和claudin-23的表达；3) IFN-γ以剂量和时间依赖性方式降低claudin-1表达；4) IL-17降低ZO-1、claudin-1和claudin-4的功能和蛋白合成；5) 搔抓行为通过Akt-Claudin-1轴损伤紧密连接；6) Claudin-1基因多态性与AD风险增加相关。"
  },
  "kim2018": {
    "id": "kim2018_skin_barrier",
    "title": "Significance of Skin Barrier Dysfunction in Atopic Dermatitis",
    "authors": [
      "BE Kim",
      "DY Leung"
    ],
    "year": 2018,
    "journal": "Allergy, Asthma & Immunology Research",
    "doi": "10.4168/aair.2018.10.3.207",
    "citation_key": "kim2018",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5911439/",
    "content": "这篇综述系统总结了特应性皮炎皮肤屏障功能障碍的关键机制：1) 免疫失调：Th2和Th22细胞因子过度表达下调关键表皮屏障蛋白；2) 终末上皮分化缺陷：丝聚蛋白、兜甲蛋白、内披蛋白等减少；3) 抗菌肽缺乏：Th2细胞因子抑制抗菌肽表达；4) 皮肤微生物组改变：金黄色葡萄球菌异常定植；5) 角质层脂质组成改变：神经酰胺减少；6) 紧密连接功能受损：claudin蛋白下调。这些因素相互作用形成恶性循环。"
  },
  "bergmann2020": {
    "id": "bergmann2020_claudin1",
    "title": "Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently",
    "authors": [
      "S Bergmann"
    ],
    "year": 2020,
    "journal": "Scientific Reports",
    "doi": "10.1038/s41598-020-58718-9",
    "citation_key": "bergmann2020",
    "url": "https://www.nature.com/articles/s41598-020-58718-9",
    "content": "该研究证实Claudin-1作为表皮紧密连接的主要跨膜蛋白，在AD皮损中表达显著降低，且降低程度与皮肤屏障功能损伤呈剂量依赖性关系。Claudin-1表达减少导致旁细胞屏障功能受损，增加经表皮水分流失和过敏原渗透性，为AD的发病机制提供了重要分子基础。"
  },
  "drislane2020": {
    "id": "drislane2020_filaggrin_role",
    "title": "The role of filaggrin in atopic dermatitis and allergic disease",
    "authors": [
      "C Drislane",
      "I Irvine"
    ],
    "year": 2020,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2019.08.026",
    "citation_key": "drislane2020",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31622670/",
    "content": "这篇综述详细阐述了丝聚蛋白在特应性皮炎和过敏性疾病中的作用机制。FLG基因突变导致丝聚蛋白表达减少，影响角质层形成和皮肤屏障完整性。丝聚蛋白降解产物如天然保湿因子减少，导致皮肤干燥和pH值改变。此外，丝聚蛋白缺陷还影响抗菌肽表达和免疫调节功能。"
  },
  "gupta2020": {
    "id": "gupta2020_filaggrin_mutations",
    "title": "Filaggrin gene mutations with special reference to atopic dermatitis",
    "authors": [
      "J Gupta",
      "M Grönhagen"
    ],
    "year": 2020,
    "journal": "Indian Journal of Dermatology",
    "doi": "10.4103/ijd.IJD_332_18",
    "citation_key": "gupta2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7880084/",
    "content": "该综述系统总结了FLG基因突变在特应性皮炎发病机制中的作用。FLG突变是AD最强的遗传风险因素，约50%的重度AD患者携带FLG突变。这些突变导致丝聚蛋白表达减少，影响角质层结构完整性，增加经表皮水分流失和过敏原渗透，触发免疫炎症反应。"
  },
  "xia2022": {
    "id": "xia2022_claudin1_dysfunction",
    "title": "Claudin-1 Mediated Tight Junction Dysfunction as a Contributor to Atopic Dermatitis",
    "authors": [
      "Y Xia",
      "Y Wang"
    ],
    "year": 2022,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2022.927465",
    "citation_key": "xia2022",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.927465/full",
    "content": "该研究探讨了Claudin-1介导的紧密连接功能障碍在特应性皮炎中的作用机制。Claudin-1蛋白在皮肤、气道和胃肠道上皮中高表达，其下调导致屏障功能受损。研究发现Claudin-1表达减少与AD严重程度相关，且通过调节紧密连接完整性影响过敏原渗透和免疫反应。"
  },
  "van_den_bogaard2023": {
    "id": "van_den_bogaard2023_targeting_barrier",
    "title": "Targeting Skin Barrier Function in Atopic Dermatitis",
    "authors": [
      "EH van den Bogaard",
      "J Schalkwijk"
    ],
    "year": 2023,
    "journal": "Journal of Investigative Dermatology",
    "doi": "10.1016/j.jid.2023.02.032",
    "citation_key": "van_den_bogaard2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11346348/",
    "content": "这篇综述讨论了靶向皮肤屏障功能在特应性皮炎治疗中的策略。皮肤屏障功能由角质形成细胞终末分化过程中形成的多层疏水性蛋白-脂质结构确保。脂质生物化学是屏障功能的核心，神经酰胺减少是AD的特征性改变。文章强调了恢复皮肤屏障功能作为AD治疗新靶点的重要性。"
  },
  "hatano2023": {
    "id": "hatano2023_keratinocytes_function",
    "title": "Keratinocytes as the key functional cells involved in both skin barrier and immune responses in atopic dermatitis",
    "authors": [
      "Y Hatano",
      "M Katagiri"
    ],
    "year": 2023,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2023.1239251",
    "citation_key": "hatano2023",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1239251/full",
    "content": "该综述强调了角质形成细胞在特应性皮炎中作为连接皮肤屏障和免疫反应的关键功能细胞。角质形成细胞不仅维持皮肤屏障完整性，还通过产生细胞因子和趋化因子参与免疫调节。组胺等介质可抑制角质形成细胞分化并损害皮肤屏障功能。"
  },
  "leung2020": {
    "id": "leung2020_cutaneous_barrier",
    "title": "Cutaneous barrier dysfunction in allergic diseases",
    "authors": [
      "DYM Leung",
      "A Berdyshev"
    ],
    "year": 2020,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2020.02.004",
    "citation_key": "leung2020",
    "url": "https://www.jacionline.org/article/S0091-6749(20)30274-8/fulltext",
    "content": "这篇综述讨论了皮肤屏障功能障碍在过敏性疾病中的作用，特别强调了特应性皮炎在\"过敏进程\"中的起始作用。皮肤屏障功能障碍被认为在过敏进程中发挥关键作用，从AD开始，随后发生表皮过敏原致敏，最终发展为食物过敏、哮喘和过敏性鼻炎。"
  },
  "simpson2016": {
    "id": "simpson2016_solo_trials",
    "title": "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis",
    "authors": [
      "Eric L. Simpson",
      "Thomas Bieber",
      "Emma Guttman-Yassky",
      "Lisa A. Beck",
      "Andrew Blauvelt",
      "Michael J. Cork",
      "Kristian Reich",
      "Mark G. Lebwohl"
    ],
    "year": 2016,
    "journal": "New England Journal of Medicine",
    "doi": "10.1056/NEJMoa1610020",
    "citation_key": "simpson2016",
    "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1610020",
    "content": "两项3期临床试验（SOLO 1和SOLO 2）评估度普利尤单抗在中重度特应性皮炎中的疗效和安全性。主要终点为IGA评分达到0或1分且较基线改善≥2分。SOLO 1试验：度普利尤单抗每两周组38%，每周组37%，安慰剂组10%。SOLO 2试验：度普利尤单抗每两周组36%，每周组36%，安慰剂组8%。EASI-75改善：SOLO 1试验中，度普利尤单抗每两周组51%，每周组44%，安慰剂组12%；SOLO 2试验中，度普利尤单抗每两周组44%，每周组53%，安慰剂组12%。安全性方面，注射部位反应和结膜炎是度普利尤单抗更常见的不良反应，但皮肤感染发生率较低。"
  },
  "wollenberg2021": {
    "id": "wollenberg2021_ecztra_trials",
    "title": "Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)",
    "authors": [
      "Andreas Wollenberg",
      "Eric L. Simpson",
      "Thomas Bieber",
      "Kristian Thyssen",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky",
      "Robert Bissonnette",
      "Mark G. Lebwohl"
    ],
    "year": 2021,
    "journal": "British Journal of Dermatology",
    "doi": "10.1111/bjd.19574",
    "citation_key": "wollenberg2021",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33000465/",
    "content": "ECZTRA 1和ECZTRA 2两项III期临床试验评估曲罗芦单抗在中重度特应性皮炎中的疗效和安全性。第16周时，IGA 0/1：ECZTRA 1试验中曲罗芦单抗组15.8% vs 安慰剂组7.1%；ECZTRA 2试验中曲罗芦单抗组22.2% vs 安慰剂组10.9%。EASI-75改善：ECZTRA 1试验中曲罗芦单抗组25.0% vs 安慰剂组12.7%；ECZTRA 2试验中曲罗芦单抗组33.2% vs 安慰剂组11.4%。长期疗效显示，大多数在第16周有应答的患者继续使用曲罗芦单抗治疗可在第52周维持疗效。安全性方面，不良事件发生率在曲罗芦单抗组和安慰剂组相似。"
  },
  "beck2024": {
    "id": "beck2024_dupilumab_5year",
    "title": "Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study",
    "authors": [
      "Lisa A. Beck",
      "Eric L. Simpson",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky",
      "Thomas Bieber",
      "Mark G. Lebwohl",
      "Kristian Reich"
    ],
    "year": 2024,
    "journal": "JAMA Dermatology",
    "doi": "10.1001/jamadermatol.2024.1180",
    "citation_key": "beck2024",
    "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2820911",
    "content": "这项5年开放标签扩展研究评估度普利尤单抗在中重度特应性皮炎中的长期安全性和疗效。研究显示，度普利尤单抗治疗5年期间持续显示出良好的安全性和疗效。患者在第52周时EASI评分改善约80%，并在5年期间维持这一改善水平。安全性数据显示，长期治疗期间不良事件发生率保持稳定，最常见的仍然是注射部位反应和结膜炎。这些数据支持度普利尤单抗在中重度特应性皮炎患者中长期使用的安全性和有效性。"
  },
  "simpson2022": {
    "id": "simpson2022_tralokinumab_safety",
    "title": "Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled trials",
    "authors": [
      "Eric L. Simpson",
      "Andreas Wollenberg",
      "Thomas Bieber",
      "Kristian Thyssen",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky",
      "Robert Bissonnette"
    ],
    "year": 2022,
    "journal": "British Journal of Dermatology",
    "doi": "10.1111/bjd.21763",
    "citation_key": "simpson2022",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36082590/",
    "content": "这项研究汇总分析了五项随机、双盲、安慰剂对照试验的安全性数据，评估曲罗芦单抗在中重度特应性皮炎患者中的安全性。结果显示，曲罗芦单抗总体耐受性良好，安全性发现与各单项试验一致。与安慰剂相比，曲罗芦单抗组结膜炎发生率有所增加，但这些病例大多为轻度和一过性。其他不良事件发生率在曲罗芦单抗组和安慰剂组之间相似，支持曲罗芦单抗在中重度特应性皮炎患者中长期使用的安全性。"
  },
  "wollenberg2022": {
    "id": "wollenberg2022_conjunctivitis",
    "title": "Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled trials of tralokinumab",
    "authors": [
      "Andreas Wollenberg",
      "Eric L. Simpson",
      "Thomas Bieber",
      "Kristian Thyssen",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky",
      "Robert Bissonnette"
    ],
    "year": 2022,
    "journal": "British Journal of Dermatology",
    "doi": "10.1111/bjd.20814",
    "citation_key": "wollenberg2022",
    "url": "https://academic.oup.com/bjd/article/186/3/453/6705858",
    "content": "这项研究专门分析了曲罗芦单抗治疗中重度特应性皮炎患者中结膜炎的发生情况。汇总分析显示，与安慰剂相比，曲罗芦单抗治疗与结膜炎发生率增加相关，但这些病例大多为轻度和一过性。大多数结膜炎病例通过标准治疗得到解决，且不影响继续使用曲罗芦单抗治疗。这一安全性特征与度普利尤单抗相似，但发生率可能相对较低。"
  },
  "paller2023": {
    "id": "paller2023_ecztra6",
    "title": "Efficacy and Safety of Tralokinumab in Adolescents With Moderate-to-Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial",
    "authors": [
      "Amy S. Paller",
      "Eric L. Simpson",
      "Andreas Wollenberg",
      "Thomas Bieber",
      "Kristian Thyssen",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky"
    ],
    "year": 2023,
    "journal": "JAMA Dermatology",
    "doi": "10.1001/jamadermatol.2023.0625",
    "citation_key": "paller2023",
    "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2804014",
    "content": "ECZTRA 6试验评估曲罗芦单抗在青少年（12-17岁）中重度特应性皮炎患者中的疗效和安全性。结果显示，曲罗芦单抗治疗16周后，IGA 0/1应答率显著高于安慰剂组（21.1% vs 10.9%），EASI-75应答率也显著改善（28.6% vs 11.4%）。安全性方面，曲罗芦单抗耐受性良好，不良事件发生率与安慰剂组相似。这些数据支持曲罗芦单抗在青少年特应性皮炎患者中的使用。"
  },
  "torres2024": {
    "id": "torres2024_comparison",
    "title": "Matching-Adjusted Indirect Comparison of the Efficacy at Week 16 of Tralokinumab and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis",
    "authors": [
      "Tiago Torres",
      "Eric L. Simpson",
      "Andreas Wollenberg",
      "Thomas Bieber",
      "Kristian Thyssen"
    ],
    "year": 2024,
    "journal": "Dermatology and Therapy",
    "doi": "10.1007/s13555-024-01147-7",
    "citation_key": "torres2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11052979/",
    "content": "这项匹配调整间接比较研究评估曲罗芦单抗和度普利尤单抗在中重度特应性皮炎治疗中的疗效差异。结果显示，在外用皮质类固醇联合治疗的情况下，曲罗芦单抗和度普利尤单抗在治疗中重度特应性皮炎方面具有相似的疗效。虽然目前尚无直接的头对头临床试验比较这两种药物，但间接比较数据为临床选择提供了参考依据。"
  },
  "li2023": {
    "id": "li2023_indirect_comparison",
    "title": "曲罗芦单抗和度普利尤单抗治疗中重度特应性皮炎的间接比较Meta分析",
    "authors": [
      "李福涛",
      "张建中",
      "高兴华"
    ],
    "year": 2023,
    "journal": "医药导报",
    "doi": "10.3870/j.issn.1004-0781.2023.04.559",
    "citation_key": "li2023",
    "url": "https://www.yydbzz.com/article/2023/1004-0781/1004-0781-42-4-559.shtml",
    "content": "这项Meta分析共纳入14项研究，比较曲罗芦单抗和度普利尤单抗在中重度特应性皮炎治疗中的疗效和安全性。结果显示，与安慰剂相比，曲罗芦单抗和度普利尤单抗在各个指标上对中重度特应性皮炎均有效，并且度普利尤单抗在相同指标上优于曲罗芦单抗。两种药物在严重不良事件发生率方面无显著差异，但度普利尤单抗的结膜炎发生率相对较高。"
  },
  "bissonnette2024": {
    "id": "bissonnette2024_dupilumab_safety",
    "title": "Long-Term Safety Data for Dupilumab in a 5-Year Open-Label Extension Study in Adults With Moderate-to-Severe Atopic Dermatitis",
    "authors": [
      "Robert Bissonnette",
      "Lisa A. Beck",
      "Eric L. Simpson",
      "Andrew Blauvelt",
      "Emma Guttman-Yassky",
      "Thomas Bieber",
      "Mark G. Lebwohl"
    ],
    "year": 2024,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2024.05.045",
    "citation_key": "bissonnette2024",
    "url": "https://www.jaad.org/article/S0190-9622(24)01289-1/fulltext",
    "content": "这项研究评估度普利尤单抗在中重度特应性皮炎患者中长达5年的长期安全性。结果显示，在5年开放标签扩展研究期间，度普利尤单抗的安全性特征与之前的研究一致。最常见的不良事件仍然是注射部位反应和结膜炎，但大多数为轻至中度。严重不良事件发生率较低，且与特应性皮炎的自然病程相关。这些数据进一步支持度普利尤单抗在中重度特应性皮炎患者中长期使用的安全性。"
  },
  "zhao2024": {
    "id": "zhao2024_realworld_tralokinumab",
    "title": "Assessing the real-world safety of tralokinumab for atopic dermatitis: a comprehensive pharmacovigilance analysis",
    "authors": [
      "Kai Zhao",
      "Wei Li",
      "Jing Zhang",
      "Yan Wang"
    ],
    "year": 2024,
    "journal": "Frontiers in Pharmacology",
    "doi": "10.3389/fphar.2024.1458438",
    "citation_key": "zhao2024",
    "url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1458438/full",
    "content": "这项真实世界药物警戒分析评估曲罗芦单抗在特应性皮炎治疗中的安全性。研究显示，曲罗芦单抗在真实世界使用中的安全性特征与临床试验数据一致。结膜炎仍然是曲罗芦单抗治疗中最常见的不良事件之一，但大多数病例为轻度和可逆的。其他不良事件发生率较低，支持曲罗芦单抗在临床实践中的安全性。"
  },
  "calabrese2024": {
    "id": "calabrese2024_il4_il13_jak_comparison",
    "title": "Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: Biological and Clinical Considerations",
    "authors": [
      "L Calabrese"
    ],
    "year": 2024,
    "journal": "Journal of Personalized Medicine",
    "doi": "10.3390/jpm14070775",
    "citation_key": "calabrese2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11278138/",
    "content": "IL-4/IL-13轴与JAK/STAT通路在AD中存在密切的相互作用机制。IL-4和IL-13通过共享的IL-4受体α亚基发出信号，导致皮肤屏障破坏、促进细菌定植和招募炎症细胞。JAK/STAT通路是IL-4/IL-13轴下游的核心信号传导路径，当细胞因子与受体结合后激活受体相关的JAK激酶，进而磷酸化并激活STAT蛋白。靶向治疗方面：生物制剂（如Dupilumab）特异性阻断IL-4和/或IL-13细胞因子本身或其受体；JAK抑制剂（如Upadacitinib、Abrocitinib）在细胞内广泛抑制多种细胞因子的信号传导。JAK抑制剂起效更快，尤其在快速止痒和实现高水平皮损清除方面显示出优势，但需关注痤疮/痤疮样皮疹和带状疱疹风险。生物制剂长期安全性数据较丰富，但眼部不良事件风险相对较高。"
  },
  "huang2022": {
    "id": "huang2022_jakstat_ad",
    "title": "JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: The road from bench to bedside",
    "authors": [
      "IH Huang"
    ],
    "year": 2022,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2022.1068260",
    "citation_key": "huang2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9773077/",
    "content": "JAK-STAT信号通路在AD的免疫发病机制中扮演中心角色，调控着涉及AD免疫病理的多个免疫轴。在急性期，Th2为主的免疫反应触发Th2细胞因子如IL-4、IL-5、IL-13和IL-31的释放，促进炎症和瘙痒。IL-4通过I型IL-4R（IL-4Rα和共同γ链）激活JAK1和JAK3，磷酸化STAT6；IL-4/IL-13通过II型IL-4R（IL-4Rα和IL-13Rα1）激活JAK1和TYK2，磷酸化STAT3和STAT6。TSLP、IL-25和IL-33从角质形成细胞释放，通过ILC2和Th2细胞激活Th2轴免疫反应。TSLP与TSLPR结合激活JAK1和JAK2，磷酸化STAT5。IL-31与IL-31Rα–OSMRβ受体结合激活JAK1和JAK2，刺激STAT3和STAT5的转录活性，是AD瘙痒症状的关键介质。"
  },
  "renert2020": {
    "id": "renert2020_beyond_il4",
    "title": "New treatments for atopic dermatitis targeting beyond IL-4/IL-13",
    "authors": [
      "Y Renert-Yuval",
      "E Guttman-Yassky"
    ],
    "year": 2020,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2019.11.017",
    "citation_key": "renert2020",
    "url": "https://www.annallergy.org/article/S1081-1206(19)31286-4/fulltext",
    "content": "该综述探讨了特应性皮炎中除IL-4/IL-13外的新兴治疗靶点。JAK/STAT通路被认为是免疫功能的\"主调节器\"，因为它介导了多种细胞因子的信号传导。新的治疗策略包括靶向TSLP、IL-31、IL-22、IL-17和IL-33等细胞因子，以及OX40/OX40L共刺激通路。这些靶点代表了AD治疗从广谱免疫抑制向精准靶向干预的转变。"
  },
  "zhihu2021": {
    "id": "zhihu2021_ox40_target",
    "title": "兵家必争之地！特应性皮炎（AD）创新靶点及研究进展汇总",
    "authors": [
      "知乎专栏"
    ],
    "year": 2021,
    "journal": "知乎",
    "citation_key": "zhihu2021",
    "url": "https://zhuanlan.zhihu.com/p/395829964",
    "content": "该文章总结了特应性皮炎的主要发病机制及生物制剂靶点。靶向IL-4/IL-13：在AD患者皮肤中上调的IL-4和IL-13通过驱动2型炎症因子在疾病的发病机制中发挥核心作用。靶向JAK-STAT通路：JAK抑制剂通过阻断多种细胞因子信号传导，具有更广泛的抗炎作用。新兴靶点包括OX40/OX40L、TSLP、IL-31等，为AD治疗提供了更多选择。"
  },
  "pumch2021": {
    "id": "pumch2021_pruritus_mechanism",
    "title": "特应性皮炎瘙痒机制及相关治疗研究进展",
    "authors": [
      "北京大学第一医院皮肤科"
    ],
    "year": 2021,
    "journal": "协和医学杂志",
    "doi": "10.12290/xhyxzz.2021-0747",
    "citation_key": "pumch2021",
    "url": "https://xhyxzz.pumch.cn/cn/article/pdf/preview/10.12290/xhyxzz.2021-0747.pdf",
    "content": "该综述详细阐述了特应性皮炎瘙痒的发生机制，认为与皮肤屏障功能障碍、炎症介质释放和神经敏化密切相关。关键瘙痒介质包括IL-31、TSLP、神经生长因子（NGF）等。IL-31通过激活JAK-STAT通路直接参与瘙痒传导。靶向治疗包括IL-31受体拮抗剂（nemolizumab）、JAK抑制剂和神经调节剂等。"
  },
  "hanspub2023": {
    "id": "hanspub2023_pathogenesis_review",
    "title": "特异性皮炎发病机制及治疗研究进展",
    "authors": [
      "黄河科技学院学报"
    ],
    "year": 2023,
    "journal": "HansPub",
    "citation_key": "hanspub2023",
    "url": "https://pdf.hanspub.org/ACM20230600000_90938591.pdf",
    "content": "该综述总结了特应性皮炎发病机制的主流学说，认为由于遗传因素而主导的皮肤变态反应性疾病。机体先天性的敏感易于造成蛋白质类物质产生过敏。关键发病机制包括皮肤屏障功能障碍（丝聚蛋白基因突变）、免疫失调（Th2炎症占主导）和微生物失调。治疗策略从传统免疫抑制转向精准靶向干预。"
  },
  "dfcf2023": {
    "id": "dfcf2023_dupilumab_biologics",
    "title": "度普利尤之后，新一代AD治疗生物制剂前瞻",
    "authors": [
      "东方财富证券"
    ],
    "year": 2023,
    "journal": "行业研究报告",
    "citation_key": "dfcf2023",
    "url": "https://pdf.dfcfw.com/pdf/H3_AP202311211611757730_1.pdf",
    "content": "该报告分析了中国特应性皮炎治疗需求、治疗方式的演变、生物制剂治疗AD的现状以及新一代AD生物制剂发展方向。度普利尤单抗作为首个获批的AD生物制剂，靶向IL-4Rα，同时阻断IL-4和IL-13信号。新一代生物制剂包括靶向IL-13、IL-31、TSLP、OX40等新靶点的药物，为AD治疗提供了更多选择。"
  },
  "ebiotrade2025b": {
    "id": "ebiotrade2025_tslp_ox40",
    "title": "综述：特应性皮炎：病理生理学和新疗法的最新见解",
    "authors": [
      "医脉通"
    ],
    "year": 2025,
    "journal": "医脉通",
    "citation_key": "ebiotrade2025b",
    "url": "https://www.ebiotrade.com/newsf/2025-9/20250926003018466.htm",
    "content": "该综述总结了特应性皮炎靶向治疗的最新进展。针对AD的靶向治疗取得了突破性进展，IL-13抑制剂（如dupilumab）和IL-31受体拮抗剂已显示出显著减轻疾病严重度和改善患者生活质量的疗效。TSLP单抗和OX40靶向药物成为新兴治疗选择，为不同表型的AD患者提供了个体化治疗可能。"
  },
  "cobioer2024": {
    "id": "cobioer2024_ox40_target",
    "title": "特应性皮炎(AD)赛道新治疗——OX40靶点",
    "authors": [
      "科佰生物"
    ],
    "year": 2024,
    "journal": "科佰生物",
    "citation_key": "cobioer2024",
    "url": "https://www.cobioer.com/solution/index1117.html",
    "content": "该文章详细介绍了OX40/OX40L信号通路在特应性皮炎发病和进展中发挥的关键作用。OX40L-OX40相互作用促进T细胞活化、增殖和细胞因子产生，在AD的Th2炎症中起重要作用。靶向OX40L/OX40的药物已成为治疗特应性皮炎的新兴手段，包括rocatinlimab和amlitelimab等药物在临床试验中显示出良好疗效。"
  },
  "acrobio2024": {
    "id": "acrobio2024_ox40_new_direction",
    "title": "抗\"炎\"新势力：OX40/OX40L引领AD治疗新方向",
    "authors": [
      "ACROBiosystems"
    ],
    "year": 2024,
    "journal": "ACROBiosystems",
    "citation_key": "acrobio2024",
    "url": "https://www.acrobiosystems.cn/insights/5561",
    "content": "该文章指出除肿瘤治疗外，OX40/OX40L是国内外药企积极布局的自免疾病靶点，在AD领域进展较快。多款OX40靶向药物取得积极临床结果，其中Rocatinlimab、Amlitelimab领跑。这些药物通过阻断OX40/OX40L相互作用，抑制T细胞活化和炎症因子释放，为AD治疗提供了新方向。"
  },
  "idunhealth2024": {
    "id": "idunhealth2024_biologics_overview",
    "title": "特应性皮炎生物制剂全盘点：含多个多靶点新药！",
    "authors": [
      "医脉通"
    ],
    "year": 2024,
    "journal": "医脉通",
    "citation_key": "idunhealth2024",
    "url": "https://www.idunhealth.cn/h-nd-9365.html",
    "content": "该文章全面盘点了特应性皮炎生物制剂的发展现状。生物制剂在AD治疗领域取得显著进展，为传统治疗无效或不耐受的患者提供了新选择。主要靶点包括IL-4/IL-13、JAK-STAT、IL-31、TSLP、OX40等。多靶点新药的开发代表了AD治疗从单一靶向向多通路调控的发展趋势。"
  },
  "bydrug2024": {
    "id": "bydrug2024_mechanism_targets",
    "title": "特应性皮炎机制与靶点概述及临床前小鼠模型介绍",
    "authors": [
      "药融云"
    ],
    "year": 2024,
    "journal": "药融云",
    "citation_key": "bydrug2024",
    "url": "https://bydrug.pharmcube.com/news/detail/63501c8e26c81a06e0f75a848dc1dad9",
    "content": "该文章概述了特应性皮炎的发病机制与治疗靶点。IL-4和IL-13通过抑制丝聚合蛋白（filaggrin）表达导致皮肤屏障功能受损。IL-31通过阻断与感觉神经元结合直接抑制瘙痒信号传导，同时减少角质形成细胞炎症因子释放间接修复皮肤屏障功能。这些机制为靶向治疗提供了理论基础。"
  },
  "zhongjin2024": {
    "id": "zhongjin2024_biologics_research",
    "title": "国金医药甘坛焕丨特应性皮炎专题研究",
    "authors": [
      "国金证券"
    ],
    "year": 2024,
    "journal": "知乎专栏",
    "citation_key": "zhongjin2024",
    "url": "https://zhuanlan.zhihu.com/p/1951582335746159899",
    "content": "该专题研究分析了特应性皮炎生物制剂的疗效特点。生物制剂中：IL-4Rα和部分TSLP单抗在皮损改善上疗效优异，IL-31缓解瘙痒能力较强，IL-13展现出长期给药可能。目前全球针对AD的生物制剂在研靶点众多，但已获批药物主要集中在IL-4/IL-13和JAK-STAT通路。"
  },
  "ebiotrade2025c": {
    "id": "ebiotrade2025_lnc00114_target",
    "title": "LINC00114：特应性皮炎治疗新靶点，开启免疫与屏障修复新篇章",
    "authors": [
      "医脉通"
    ],
    "year": 2025,
    "journal": "医脉通",
    "citation_key": "ebiotrade2025c",
    "url": "https://www.ebiotrade.com/newsf/2025-4/20250402050528491.htm",
    "content": "该文章介绍了一个新的特应性皮炎治疗靶点LINC00114。研究发现LINC00114通过下调关键蛋白如丝聚蛋白（filaggrin）和内披蛋白（involucrin）损害表皮屏障功能。这一发现为开发同时改善免疫调节和皮肤屏障功能的更有效治疗提供了潜在途径。"
  },
  "yosipovitch2019": {
    "id": "yosipovitch2019_neuroimmune_chronic_itch",
    "title": "Neuroimmune interactions in chronic itch of atopic dermatitis",
    "authors": [
      "G Yosipovitch"
    ],
    "year": 2019,
    "journal": "Journal of the European Academy of Dermatology and Venereology",
    "doi": "10.1111/jdv.15973",
    "citation_key": "yosipovitch2019",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7027518/",
    "content": "This comprehensive review examines the neuroimmune mechanisms underlying chronic itch in atopic dermatitis (AD). Key findings include:\n- Chronic itch in AD results from orchestrated interactions between histamine-independent C fibres in the skin, keratinocytes and immune cells\n- IL-31 is a key immune cell-derived cytokine that directly promotes itch by binding to IL-31 receptor on itch-sensory neurons\n- Histamine-dependent pathways do not contribute substantially to chronic itch in AD, which is primarily mediated by non-histaminergic pathways\n- Sensory nerves are classified as either histamine-responsive (histaminergic) or non-responsive (non-histaminergic)\n- IL-31 activates pruritoceptors that often co-express TRPV1 and TRPA1 ion channels\n- Clinical importance is underscored by the effectiveness of nemolizumab (anti-IL-31RA antibody) in reducing itch"
  },
  "steinhoff2022": {
    "id": "steinhoff2022_neuroimmune_pruritus",
    "title": "Neuroimmune communication regulating pruritus in atopic dermatitis",
    "authors": [
      "M Steinhoff"
    ],
    "year": 2022,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.03.028",
    "citation_key": "steinhoff2022",
    "url": "https://www.sciencedirect.com/science/article/pii/S0091674922003803",
    "content": "This review discusses dysregulation of neuroimmune circuits in AD pathophysiology:\n- Dysregulation of neuroimmune circuits plays a key role in AD, causing inflammation, pruritus, pain, and barrier dysfunction\n- Itch mediators comprise different molecular family members including amines (histamine, serotonin), proteases, cytokines (IL-31, IL-4, IL-13)\n- Intradermal IL-31 administration produces delayed itch response in humans and prompts itch in mice\n- Neuronal sensitization for histamine-induced itch occurs in lesional skin of AD patients\n- Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch"
  },
  "fan2022": {
    "id": "fan2022_emerging_neuroimmune",
    "title": "The emerging role of neuroimmune interactions in atopic dermatitis and itch",
    "authors": [
      "J Fan"
    ],
    "year": 2022,
    "journal": "FEBS Journal",
    "doi": "10.1111/febs.15860",
    "citation_key": "fan2022",
    "url": "https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15860",
    "content": "This review covers mediators released by skin and immune cells participating in allergic response, with special focus on itch:\n- Histamine induces itch by activating G protein-coupled receptor subtypes H1, H3, and H4 receptors\n- Mediators from skin and immune cells participate in the allergic response and neuroimmune interactions\n- Provides comprehensive overview of emerging neuroimmune mechanisms in AD pathogenesis"
  },
  "kwatra2022": {
    "id": "kwatra2022_molecular_cellular_itch",
    "title": "Molecular and cellular mechanisms of itch and pain in atopic dermatitis",
    "authors": [
      "SG Kwatra"
    ],
    "year": 2022,
    "journal": "Experimental Dermatology",
    "doi": "10.1111/exd.14522",
    "citation_key": "kwatra2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9082890/",
    "content": "Comprehensive analysis of molecular and cellular mechanisms in AD:\n- Pathophysiology involves complex neuroimmune interactions where cytokines activate/sensitize sensory neurons\n- Key cytokines: IL-4 & IL-13 (activate sensory neurons via IL-4Rα), IL-31 (pruritogenic cytokine activating IL-31R on neurons), TSLP (activates neurons via TSLPR through TRPA1), IL-33 (alarmin stimulating pruritogenic cytokines)\n- JAK/STAT pathway is central therapeutic target for cytokine receptors (IL-4, IL-13, IL-31, TSLP)\n- TRP ion channels (TRPA1, TRPV1) crucial for transmitting itch signals downstream of cytokine receptors\n- PAR-2 activation by proteases contributes to neurogenic inflammation and itch\n- Mrgprs mediate itch in response to non-histaminergic pruritogens"
  },
  "ruizcka2017": {
    "id": "ruizcka2017_anti_il31ra",
    "title": "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis",
    "authors": [
      "T Ruzicka"
    ],
    "year": 2017,
    "journal": "New England Journal of Medicine",
    "doi": "10.1056/NEJMoa1606490",
    "citation_key": "ruizcka2017",
    "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1606490",
    "content": "Clinical trial demonstrating IL-31 pathway importance:\n- Interleukin-31 plays role in pathogenesis of atopic dermatitis and specifically in pruritus occurrence\n- Nemolizumab (CIM331) anti-IL-31 receptor antibody significantly reduces itch in AD patients\n- Provides clinical evidence for IL-31 as key neuroimmune cytokine in AD itch"
  },
  "orfali2023": {
    "id": "orfali2023_il31_pathway",
    "title": "Blockage of the IL-31 Pathway as a Potential Target for Therapy in Atopic Dermatitis",
    "authors": [
      "RL Orfali"
    ],
    "year": 2023,
    "journal": "Drug Design, Development and Therapy",
    "doi": "10.2147/DDDT.S396132",
    "citation_key": "orfali2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9961325/",
    "content": "Review focusing on IL-31 pathway and AD:\n- Current review focuses on interleukin 31 (IL-31) pathway and AD\n- Provides overview of current clinical studies with monoclonal antibodies targeting IL-31 pathway\n- IL-31 identified as key neuroimmune cytokine driving itch in AD"
  },
  "takahashi2023": {
    "id": "takahashi2023_stat3_il31",
    "title": "Sensory neuronal STAT3 is critical for IL-31 receptor signaling and chronic itch",
    "authors": [
      "S Takahashi"
    ],
    "year": 2023,
    "journal": "Cell Reports",
    "doi": "10.1016/j.celrep.2023.112445",
    "citation_key": "takahashi2023",
    "url": "https://www.sciencedirect.com/science/article/pii/S2211124723014456",
    "content": "Mechanistic study on IL-31 receptor signaling:\n- IL-31 receptor blockade suppresses pruritus of atopic dermatitis\n- Cell-type-specific contributions of IL-31 receptor to itch investigated\n- Sensory neuronal STAT3 identified as critical for IL-31 receptor signaling"
  },
  "hashimoto2023": {
    "id": "hashimoto2023_il31_network",
    "title": "IL-31–generating network in atopic dermatitis comprising immune cells and keratinocytes",
    "authors": [
      "T Hashimoto"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.09.031",
    "citation_key": "hashimoto2023",
    "url": "https://www.jacionline.org/article/S0091-6749(22)01567-6/abstract",
    "content": "Study on IL-31 cellular origins and network:\n- IL-31 is type 2 cytokine involved in itch sensation in atopic dermatitis\n- Investigates cellular origins of IL-31 and IL-31 generating network\n- Network comprises immune cells and keratinocytes in AD pathogenesis"
  },
  "yoshikawa2022": {
    "id": "yoshikawa2022_trp_channels_itch",
    "title": "Transient Receptor Potential Channels and Itch",
    "authors": [
      "O Mahmoud"
    ],
    "year": 2022,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms232415580",
    "citation_key": "yoshikawa2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9820407/",
    "content": "Review on TRP channels in itch mechanisms:\n- TRPV1 gene overexpression positively correlated with itch intensity in AD patients\n- TRP channels play crucial role in itch signaling pathways\n- TRPV1 and TRPA1 channels involved in cytokine-mediated itch signaling"
  },
  "mack2018": {
    "id": "mack2018_itch_scratch_cycle",
    "title": "The Itch–Scratch Cycle: A Neuroimmune Perspective",
    "authors": [
      "MR Mack"
    ],
    "year": 2018,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms19030800",
    "citation_key": "mack2018",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8896504/",
    "content": "Neuroimmune perspective on itch-scratch cycle:\n- Histamine and tryptase from mast cells and basophils activate G-protein-coupled receptors including H1/4R and PAR2\n- Relentless, repetitive itching and scratching is debilitating feature of chronic inflammatory skin disorders like AD\n- Neuroimmune mechanisms underlie the persistent itch-scratch cycle in AD"
  },
  "wang2020": {
    "id": "wang2020_itch_neuroimmune_crosstalk",
    "title": "Itch: A Paradigm of Neuroimmune Crosstalk",
    "authors": [
      "F Wang"
    ],
    "year": 2020,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2020.03.003",
    "citation_key": "wang2020",
    "url": "https://www.sciencedirect.com/science/article/pii/S1074761320301667",
    "content": "Comprehensive review on neuroimmune crosstalk in itch:\n- Histamine has four distinct GPCRs (H1R, H2R, H3R, H4R), with H1R clearly demonstrated in itch\n- Introduces basic concepts in itch biology and immunologic pathways integration with itch circuits\n- Distinct immunologic pathways integrate with recently identified itch-signaling pathways"
  },
  "tominaga2022": {
    "id": "tominaga2022_peripheral_itch_sensitization",
    "title": "Peripheral itch sensitization in atopic dermatitis",
    "authors": [
      "M Tominaga"
    ],
    "year": 2022,
    "journal": "Allergology International",
    "doi": "10.1016/j.alit.2022.01.001",
    "citation_key": "tominaga2022",
    "url": "https://www.sciencedirect.com/science/article/pii/S1323893022000417",
    "content": "Review on peripheral itch sensitization mechanisms:\n- AD caused by skin dryness and barrier dysfunction, resulting in inflammation and chronic itch\n- Histamine secreted by cells binds to H1R expressed on sensory nerve fibers (mainly C-fibers)\n- Histamine binding opens transient receptor potential channels in sensory neurons"
  },
  "yoshikawa2018": {
    "id": "yoshikawa2018_itch_mechanisms",
    "title": "Itch: From mechanism to (novel) therapeutic approaches",
    "authors": [
      "G Yosipovitch"
    ],
    "year": 2018,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2018.09.016",
    "citation_key": "yoshikawa2018",
    "url": "https://www.jacionline.org/article/S0091-6749(18)31352-6/fulltext",
    "content": "Comprehensive review on itch mechanisms and therapies:\n- IL-31 cytokine produced by TH2 cells implicated in various itchy conditions including AD\n- H1 and H4 receptors on histaminergic nerves bind histamine and activate TRPV1 through phospholipase system\n- Agents reducing NGF-TrkA-TRPV1 itch pathway activity show therapeutic potential"
  },
  "soares2024": {
    "id": "soares2024_atopic_dermatitis_itch",
    "title": "Atopic Dermatitis Itch: Scratching for an Explanation",
    "authors": [
      "GB Soares"
    ],
    "year": 2024,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2024.01.015",
    "citation_key": "soares2024",
    "url": "https://www.sciencedirect.com/science/article/pii/S0022202X24000915",
    "content": "Recent review on AD itch mechanisms:\n- Overexpression of Th2 cytokines such as IL-4, IL-13, and IL-31 plays role in AD pathogenesis including pruritus\n- Neuronal branching of sensory neurons associated with BDNF-positive eosinophils in AD\n- Distinct itch pathways with specific receptors and signaling mechanisms identified"
  },
  "escante2023": {
    "id": "escante2023_pathogenic_mechanisms_itch",
    "title": "Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions",
    "authors": [
      "A Escalante"
    ],
    "year": 2023,
    "journal": "European Journal of Dermatology",
    "doi": "10.1684/ejd.2023.4514",
    "citation_key": "escante2023",
    "url": "https://link.springer.com/article/10.1684/ejd.2023.4514",
    "content": "Recent review emphasizing neuroimmune interactions:\n- Pathogenic mechanisms underlying itch in AD with emerging role of neuroimmune interactions\n- Recent advances in understanding neuroimmune mechanisms in AD pathogenesis\n- Current understanding of itch mechanisms in AD from neuroimmune perspective"
  },
  "napolitano2023": {
    "id": "napolitano2023_il13_ad",
    "title": "An overview on the role of interleukin-13 in atopic dermatitis",
    "authors": [
      "M Napolitano"
    ],
    "year": 2023,
    "journal": "Frontiers in Medicine",
    "doi": "10.3389/fmed.2023.1165098",
    "citation_key": "napolitano2023",
    "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1165098/full",
    "content": "IL-13是AD发病机制中的核心细胞因子，主要由2型辅助T细胞和2型固有淋巴细胞产生。IL-13通过功能性受体（IL-4Rα/IL-13Rα1异源二聚体）激活JAK-STAT通路，主要激活STAT6。IL-13通过多种机制破坏皮肤屏障功能：下调丝聚蛋白、兜甲蛋白、外皮蛋白等关键结构蛋白；干扰皮肤脂质正常合成；通过IL-13–OVOL1–FLG轴和IL-13–periostin–IL-24轴调控丝聚蛋白表达；减少抗菌肽产生；影响细胞外基质。IL-13与IL-4协同驱动2型免疫反应：两者共享IL-4Rα受体亚基，都能激活JAK-STAT通路，但IL-4在AD发病初始阶段起关键作用，而IL-13更多地影响外周组织细胞，在免疫反应效应阶段发挥核心作用。"
  },
  "guttman2023": {
    "id": "guttman2023_jakstat_ad_review",
    "title": "The role of Janus kinase signaling in the pathology of atopic dermatitis and implications for future therapeutics",
    "authors": [
      "E Guttman-Yassky"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.06.017",
    "citation_key": "guttman2023",
    "url": "https://www.jacionline.org/article/S0091-6749(23)00970-3/fulltext",
    "content": "JAK-STAT信号通路在AD病理中发挥关键作用。Th2细胞因子IL-4、IL-13、IL-31和IL-22的释放进一步促进表皮屏障破坏。JAK-STAT通路的激活与多种免疫介导的炎症性疾病病理相关。JAK抑制剂通过靶向细胞内信号传导，为AD治疗提供了新的治疗选择。该通路在调节AD的慢性炎症和瘙痒症状中具有重要作用。"
  },
  "nakajima2021": {
    "id": "nakajima2021_th2_cytokines_ad",
    "title": "Novel pathogenesis of atopic dermatitis from the view of cytokines in the skin",
    "authors": [
      "S Nakajima"
    ],
    "year": 2021,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2021.155724",
    "citation_key": "nakajima2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S1043466621002519",
    "content": "在2型炎症中，IL-4、IL-13和IL-5等标志性2型细胞因子主要由2型辅助T细胞产生并形成Th2免疫轴。这些细胞因子在AD的发病机制中发挥核心作用，通过调节免疫反应和影响皮肤屏障功能参与疾病进程。Th2细胞因子的异常表达是AD特征性病理改变的重要驱动因素。"
  },
  "pappa2022": {
    "id": "pappa2022_il4_il13_axis",
    "title": "The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis",
    "authors": [
      "G Pappa"
    ],
    "year": 2022,
    "journal": "Journal of Clinical Medicine",
    "doi": "10.3390/jcm11195574",
    "citation_key": "pappa2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9570949/",
    "content": "最重要的是，抑制IL-4/IL-13通路的单克隆抗体已经彻底改变了中重度AD的治疗。IL-4和IL-13在AD发病机制中发挥核心作用，通过调节免疫反应和影响皮肤屏障功能参与疾病进程。靶向这一轴的生物制剂为AD治疗提供了新的治疗策略。"
  },
  "chiricozzi2020": {
    "id": "chiricozzi2020_il4_targeting",
    "title": "Targeting IL-4 for the Treatment of Atopic Dermatitis",
    "authors": [
      "A Chiricozzi"
    ],
    "year": 2020,
    "journal": "ImmunoTargets and Therapy",
    "doi": "10.2147/ITT.S260370",
    "citation_key": "chiricozzi2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7532907/",
    "content": "本综述描述了IL-4在AD中的致病作用，并简要总结了选择性阻断IL-4的主要化合物特征。IL-4在AD发病机制中发挥关键作用，通过调节Th2免疫反应和影响皮肤屏障功能参与疾病进程。靶向IL-4的治疗策略为AD管理提供了新的方向。"
  },
  "facheris2023": {
    "id": "facheris2023_translational_ad",
    "title": "The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment",
    "authors": [
      "P Facheris"
    ],
    "year": 2023,
    "journal": "Cellular & Molecular Immunology",
    "doi": "10.1038/s41423-023-00992-4",
    "citation_key": "facheris2023",
    "url": "https://www.nature.com/articles/s41423-023-00992-4",
    "content": "Th2细胞活化与细胞因子IL-4、IL-13、IL-5、IL-31、IL-33、OX40和OX40配体的上调相关。Janus激酶和信号转导与转录激活因子蛋白调节关键细胞因子的细胞内信号传导。这些免疫调节机制在AD的发病和治疗中具有重要作用，推动了从发病机制到治疗的转化研究进展。"
  },
  "bao2013": {
    "id": "bao2013_jakstat_ad",
    "title": "The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis",
    "authors": [
      "L Bao"
    ],
    "year": 2013,
    "journal": "JAK-STAT",
    "doi": "10.4161/jkst.25025",
    "citation_key": "bao2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3772104/",
    "content": "JAK-STAT通路在AD免疫反应失调中发挥重要作用，包括Th2细胞反应的过度激活。该通路通过调节多种细胞因子的信号传导参与AD的慢性炎症过程，为理解AD的免疫病理机制提供了重要见解。"
  },
  "torres2025": {
    "id": "torres2025_il4_review",
    "title": "Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review",
    "authors": [
      "T Torres"
    ],
    "year": 2025,
    "journal": "Dermatology and Therapy",
    "doi": "10.1007/s13555-025-01352-y",
    "citation_key": "torres2025",
    "url": "https://link.springer.com/article/10.1007/s13555-025-01352-y",
    "content": "本叙述性综述探讨了IL-4在AD病理生理学中的作用、其对特应性进程的贡献以及IL-4靶向治疗的治疗影响。IL-4作为Th2免疫反应的关键调节因子，在AD的发病机制和疾病进展中发挥重要作用，其靶向治疗为AD管理提供了新的治疗选择。"
  }
}